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PREFACE 
During my time at medical school, some of my classmates and I had the opportunity to 
participate in an elective course in Bhubaneshwar, India. We were to study diabetes in a 
hospital for three weeks, just before Christmas. We were all very eager to experience the health 
care, food and culture. I was up every morning at sunrise for a morning walk. I watched the 
‘wallahs’ selling chai from sizzling pots, the kids washing and playing outside their houses, the 
women sweeping the streets, and smelled the garbage burning in small piles along the road. 
Many of us longed for home; we ordered pizza to get a break from all the curries; we took turns 
in the bathroom with the feared “Delhi belly”, and the coffee and “kokosbollar” that our teacher 
brought from Sweden were finished after a few days. This was my first trip to India, but little 
did I know that it would be the first of many to the incredible country that has its own special 
place in my heart. 
A few months after we came home, it was time to plan for the degree project that was to include 
an entire semester. I had no experience of research, and all I knew was that I wanted to go back 
to India. I started to go through the professors on the Karolinska Institutet’s website, one by 
one. I put everyone who had a connection with India on a list, and finally I marked Cecilia’s 
name with yellow highlight, as I found her research projects the most exciting. On 15 February 
2013, I walked into Cecilia’s office for our first meeting. There were souvenirs, fabrics and all 
kinds of art from around the world all over the office. She offered me a small samosa-shaped 
cake and said: “I have this antibiotic prescribing project in Ujjain. When would you like to 
go?” When I left her office, I felt that this was the beginning of a new adventure. 
In the autumn of 2013, I left a rainy and dark Sweden for a couple of months in a sunny and 
colourful Ujjain, after being awarded a Minor Field Study scholarship from the Swedish 
International Development Cooperation Agency (Sida). Megha, my co-supervisor, welcomed 
me with open arms and guided me through the college and the hospitals, introduced me to the 
research project and taught me how to eat curries with roti, using only my right hand. From 
early morning to late afternoon, six days a week, I sat opposite Megha at the large desk in her 
office, where I analysed data, interpreted results and wrote my first manuscript. I also had the 
opportunity to visit the two hospitals where the data were collected, and to meet some of the 
clinicians, which was very interesting. In the evenings I walked the streets of Ujjain, taking 
photographs, sipping burning hot chai from small plastic cups, and thinking of the next 
analysis. I learned so much during those months in Ujjain; it was one of the most important 
journeys I have made for my professional and personal development. Barely a year later, I 
returned to Ujjain for my second project in the research group, after being admitted to the 
Karolinska Institutet summer research school for medical students. 
In January 2016, after a three-month exchange in Oman, I graduated from Karolinska Institutet. 
Two weeks later, I stepped into the morning rounds at Herlev Hospital in Copenhagen to start 
my internship (allmäntjänstgöring). One year and numerous “rugbrødsmadder”, miles by bike, 
and night shifts later, I returned to Stockholm with a medical certificate. By then, it was time 
to apply for residency (specialisttjänstgöring). I opted for the field of clinical physiology. I have 
always been attracted to physiology, and it fascinated me to specialize in the area of cardiac 
ultrasonography, echocardiography (ECHO), where logical reasoning and advanced 
technology are key issues, and where I could put all my energy into exploring small details to 
help clinicians move forward in the management of their patients. 
My work at the Department of Clinical Physiology has increased my understanding of the 
importance of diagnostics and its impact on the management of the patients. We diagnose, 
evaluate and conduct follow ups with ECHO, a method that has also been implemented in some 
resource-limited settings with successful results as it is less costly and often requires less 
personnel compared to many other imaging methods. When analysing the data from Ujjain, I 
was surprised that very few of the registered diagnoses were confirmed by diagnostic methods. 
I believe it is essential to highlight the need of diagnostic methods as a clinical tool at hospitals 
in such areas, where underdiagnosing of infectious diseases is common, and patients are often 
prescribed antibiotics on clinical suspicion of infection. The most common infectious disease 
that we encounter at the Department of Clinical Physiology is infective endocarditis (IE). 
ECHO is important for the diagnosis and management of patients with IE. When I analysed the 
data from the two hospitals in Ujjain, I discovered that only 9 patients out of 243,774 admitted 
to the hospitals between 2008 and 2017 were registered with IE. Therefore, I began to think 
about how to optimize the diagnostics and management of patients with IE in resource-limited 
settings using ECHO. Could the ECHO findings say something about bacterial aetiology in 
these patients, making it possible to guide the treatment of patients in settings with limited 
access to diagnostic methods? And so, the idea of how to complement the studies of antibiotic 
prescribing in Ujjain with a study of a diagnostic method; ECHO, that could improve the 
management of an infectious disease; IE, began to grow. I contacted Cecilia and she was 
positive. I talked to Maria, who was then the head of the Department of Clinical Physiology. 
She gave me the opportunity to conduct my doctoral studies in parallel with my clinical work 
and was also willing to be my co-supervisor. A detailed plan took form during the spring, and 
in June 2018 I was registered as a doctoral student. The day before the registration seminar, I 
was admitted to the Karolinska Institutet Research School for Clinicians in Epidemiology, a 
two-year programme including all compulsory doctoral courses. The research school formed 
the best possible foundation for me as a young researcher. I found great satisfaction in being 
able to create and understand statistical analyses, to discuss scientific arguments and be inspired 
by well performed and presented research. I have had the opportunity to teach medical students, 
and to present my research at international conferences, which has been immensely inspiring. 
I think research offers an endless opportunity to develop, learn and teach. When our work 
benefits heath care and patients, I feel that we have achieved one of the most noble outcomes.
  
ABSTRACT 
Background: Antibiotic resistance is a globally emerging health challenge. In resource-limited 
settings, the burdens of infectious diseases and of antibiotic resistance are the highest. The 
World Health Organization (WHO) has stated that high and uncontrolled use of antibiotics in 
resource-limited settings contributes to the increasing prevalence of antibiotic resistance in 
such areas. Improvements should be based on knowledge about current antibiotic use, 
preventing the spread of infections, and the implementation and/or development of diagnostic 
methods for the improved management of infectious diseases. Limited access to diagnostic 
methods complicates the management of infectious diseases in resource-limited settings and 
increases the risk of disregarding severe infectious diseases, such as infective endocarditis (IE). 
Therefore, it is important to evaluate diagnostic methods that can improve the management of 
infectious diseases in such settings. Evaluating whether the findings of echocardiography 
(ECHO) could give a suggestion of the bacterial aetiology in patients with IE in a high-income 
setting might provide valuable information for the implementation of ECHO in resource-
limited settings. 
 
Aims: To map and describe the antibiotic prescribing practices and to highlight areas of 
improvement in the management of in-patients with infectious diseases in a resource-limited 
setting in India. Further to assess whether specific manifestations detected by ECHO were 
associated with certain bacterial species in patients with IE in a high-income setting in Sweden.  
 
Methods: The studies for Papers I-III were conducted in a teaching hospital (TH) and a non-
teaching (NTH) hospital in India. Two were prospective, cross-sectional studies (I and II) and 
one was a time series analysis (III). Paper IV was conducted in Stockholm, Sweden, as a 
register-based cohort study. For Paper I, antibiotic use was analysed at the medical intensive 
care units (ICUs) at the two hospitals in India. For Paper II, antibiotic prescribing practices 
were analysed with a focus on infectious diagnoses at the paediatric departments at the two 
hospitals in India. For Paper III, time series analyses over a 10-year period (2008–2017) were 
conducted to follow antibiotic prescribing over time among patients with severe infections at 
the NTH and the TH in India. For Paper IV, associations between IE manifestations detected 
by ECHO and bacterial species were assessed from a cohort of patients with IE obtained from 
the Swedish National Registry of Infective Endocarditis (SRIE). 
 
Main findings: High percentages of patients at the medical ICUs were prescribed antibiotics 
at both hospitals (4,843 of 6,141 patients, 70%) although less than 25% of the patients were 
registered with an infection-associated diagnosis (I). At the paediatric departments, antibiotic 
use among patients with either acute gastroenteritis, respiratory tract infections, enteric fever, 
viral fever or unspecified fever was more common at the NTH (2,088 patients, 84%) compared 
with the TH (224 patients, 44%; P < 0.001). Broad-spectrum antibiotics were commonly 
prescribed at both hospitals, and less than 40% of the prescribed antibiotics at both hospitals 
were compliant to the national list of essential medicines (37% at the TH and 24% at the NTH; 
P < 0.05) (II). From 2008 to 2017, the overall rate of antibiotic prescribing for patients with 
severe infections, as well as prescribing of first- and second-line antibiotics and so-called fixed-
dose combinations (FDCs) of antibiotics increased in the NTH (P < 0.05). In the TH, the overall 
antibiotic prescribing did not change significantly, although the prescribing of second- and 
third-line antibiotics and FDCs of antibiotics increased during the study period (P < 0.05) (III). 
Among patients with IE, associations were seen between aortic valve vegetation and 
Enterococcus faecalis among patients with native aortic valves, between mitral valve 
vegetation and streptococci of group B or viridans group streptococci, between tricuspid valve 
vegetation and Staphylococcus aureus among patients with intravenous drug abuse, and 
between perivalvular abscesses as well as cardiovascular implantable electronic device 
(CIED)-associated IE and coagulase-negative staphylococci (all P < 0.05) (IV). 
 
Conclusions: Antibiotic prescribing was high at the ICUs and paediatric departments at the 
NTH and the TH, also among patients presenting with no infection-associated diagnoses or 
with diagnoses for which antibiotic treatments are not recommended. Broad-spectrum 
antibiotics were commonly prescribed at both hospitals. From 2008 to 2017, prescribing of 
second-line antibiotics and FDCs of antibiotics among patients with severe infections increased 
at both hospitals. The findings suggest that there is a need for improved antibiotic prescribing 
and management of infectious diseases. A major problem in this setting as well as in similar 
resource-limited settings is the limited use of diagnostics, which are needed to guide the 
treatment and follow-up of infectious diseases. Limited use of diagnostics also increases the 
risk of underdiagnosing infectious diseases. Very few cases of IE were registered at the NTH 
and TH, which might be a result of the limited use of diagnostics. ECHO is an effective method 
for the diagnosis, evaluation and follow-up of patients with IE, successfully implemented in 
high-income settings. ECHO can be used to identify cardiac manifestations of IE but might 
also give a suggestion of bacterial aetiology as some IE manifestations detected by ECHO have 
been shown to be associated with certain bacterial species. These findings could possibly be 
useful also in resource-limited settings, where ECHO might improve the management of 
patients with IE. 
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1 INTRODUCTION 
1.1 ANTIBIOTIC RESISTANCE 
1.1.1 Antibiotic resistance from a global perspective 
Already in his Nobel Prize speech in 1945, the father of penicillin, Alexander Fleming, warned 
that bacteria could become resistant to antibiotics (1, 2). Since then, antibiotic resistance has 
developed into a global problem that continues to increase every year (1). Antibiotic resistance 
emerges when bacteria change their response to antibiotics, so they are not harmed or destroyed 
(3). To be precise, mutations or vertical and horizontal gene transfer occur in the bacteria, and 
selection pressure from antibiotic use contributes to the development of strains of bacteria that 
are less harmed by antibiotic treatment (4). Humans or animals that become infected by 
antibiotic-resistant bacteria might suffer because antibiotic treatments will be less effective or 
totally dysfunctional. The treatment alternatives for the infection caused by resistant bacteria 
will be reduced, or in the worst case scenario there will be no effective treatment available for 
such infections (5). Antibiotic resistance can occur because of extensive and/or inappropriate 
use of antibiotics, as the bacteria in the infected person progressively evolve decreased 
susceptibility (4). Infections with antibiotic-resistant bacteria can also occur if a person is 
infected by resistant bacteria or if bacteria in the human microbiome are resistant to antibiotics 
and transfer their resistance to other pathogens (4). Antibiotic resistance can affect anyone, 
regardless of age, sex and ethnicity. It is known that poor hygiene increases the risk that 
resistant bacteria will spread among populations, which is a major problem in resource-limited 
areas with poorly controlled hygiene practices (6). As more bacterial strains develop resistance, 
more classes of antibiotics will become less effective. If we do not address the problem, simple 
infections will eventually be life-threatening and cause unnecessary deaths (1, 7, 8). Thus, 
many of our common health care procedures worldwide such as surgery, organ transplantation 
and cancer therapy can be complicated because of antibiotic resistance, as effective antibiotic 
treatment is essential for the safety of these procedures (4, 9). 
In 2015, the World Health Organization (WHO) adopted a global action plan on antimicrobial 
resistance, aiming to ensure the long-term, successful prevention and treatment of infectious 
diseases and to keep antibiotics as an available, effective and safe treatment with quality-
assured medicines, prescribed in a rational way (10). A further aim for the Member States was 
to prepare national, multi-sectoral action plans that should be implemented through education 
about good prescribing, information on how antibiotic resistance arises and spreads, and by 
highlighting the need for sustainable investment through research and development (10). 
During 2018–2019, 117 Member States had prepared national action plans, 36 were in the 
planning phase, but six had no national action plan (11). 
1.1.2 Antibiotic resistance in resource-limited settings 
Measures to contain and slow down the emergence of antibiotic resistance are particularly 
important in resource-limited settings where the burdens of infectious diseases and of antibiotic 
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resistance are the greatest (4, 12, 13). A major challenge in resource-limited settings is to assure 
the balance between improved antibiotic access for appropriate therapeutic uses and to restrict 
inappropriate access to antibiotics (13, 14). The emergence and spread of antibiotic resistance 
are worse where antibiotics can be purchased without a prescription, which is common in low- 
and middle-income countries (LMICs) (4, 6, 15-17). Another problem involves environmental 
factors that contribute to the dissemination of antibiotic resistance in LMICs, such as drug 
manufacturing, hospital waste, and antibiotic overuse in food animals (14). As LMICs often 
have fewer public health protective measures compared with high-income countries, people in 
these areas are often more exposed to environmental or human reservoirs of antibiotic-resistant 
bacteria (14). To minimize the emergence of antibiotic resistance that arises from the interface 
between humans, animals and the environmental factors, the so-called “One Health” approach 
is recommended (14). This aims for better public health outcomes by planning and 
implementing programmes, policies, legislation and research, through multidisciplinary 
collaborations (10, 14). The WHO, the World Organization for Animal Health, and the Food 
and Agriculture Organization of the United Nations are examples of organizations that are 
actively working with LMICs to develop partnerships, antibiotic stewardship programmes and 
strategic groups, to contain the emergence of antibiotic resistance (10, 14, 16). 
1.2 ANTIBIOTIC USE 
Antibiotics are used after being prescribed or sometimes after their purchase as over-the-
counter medicines for the treatment of, or prevention of, infectious diseases in human health 
care. Antibiotics are also used in animal production and in agriculture. The use of antibiotics 
needs to be improved globally to avoid the further development of antibiotic resistance. There 
is a need for improvements in antibiotic prescribing practices and also in the prevention of the 
spread of infections to reduce the need for antibiotic treatments (5). The increasing prevalence 
of antibiotic resistance contributes to high costs, as the need for a greater number of treatments 
and more extensive treatments increases, hospital stays are extended, and workplace production 
decreases as people become ill and even die from infections that cannot be treated (12). To 
reduce and rationalize the use of antibiotics, there is a need for spreading knowledge about how 
antibiotic resistance occurs, how infections can be prevented and how to map resistance 
patterns and the use of antibiotics by continuous research (16, 18). Further, investments in new 
medicines, vaccinations, information on good hygiene and sanitation routines and 
implementation and/or development of diagnostic methods for infectious diseases are required 
(12). It is also important to control the use of antibiotics outside the human sector, for instance 
in animal husbandry and agriculture and in the food industry as these are significant areas of 
antibiotic overuse (7). All improvements and developments in improving actions are important 
and are required in all countries every day. 
This thesis focuses on the prescribing of antibiotics for, and management of, infectious diseases 
among in-patients: i.e., patients who are hospitalized while they receive their treatment. 
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1.2.1 Rational use of antibiotics 
When antibiotics are to be prescribed, it is important that this is done correctly to avoid the 
development of antibiotic resistance (19). Antibiotics should only be used for relevant 
indications, with the correct choice, in the correct dosage, for the correct treatment duration 
and by a suitable route of administration (20). The aim should be targeted treatment: i.e., 
treatment with an antibiotic that is effective against the pathogen causing the infection (21-23). 
Antibiotics are often prescribed empirically for in-patients when infectious aetiology is 
suspected, i.e., without knowledge of which bacteria caused the potential infection. Empirical 
antibiotic treatment should be chosen for the most likely pathogen causing the infection and 
site of infection, adjusted for local susceptibility patterns, and if necessary, reconsidered after 
daily examination and clinical evaluation of the patient (18, 24). Ideally, empirical treatment 
should be replaced with a targeted treatment regimen after results from diagnostics such as 
pathogen cultures and susceptibility tests (25). The WHO recommends empirical antibiotic 
treatment only if certain severe infectious diseases are suspected: epiglottitis, pneumonia, 
peritonitis, pyelonephritis, cellulitis, erysipelas, septic arthritis, infective endocarditis (IE), 
meningitis and sepsis (25). There are detailed international guidelines for empirical antibiotic 
prescribing when any of these diagnoses are suspected (23, 25, 26). However, in resource-
limited settings with reduced or absent access to diagnostic methods, most of the antibiotic 
prescriptions are empirical, based on a clinical suspicion of infection. In such settings, 
treatments with so-called broad-spectrum antibiotics are commonly prescribed, namely 
antibiotics that cover a larger number of bacteria than the narrower-spectrum, more targeted 
alternatives, also if these are not recommended for the suspected diagnosis (4, 16, 27, 28). 
Broad-spectrum antibiotics are not always more effective than more targeted, narrower-
spectrum types (29, 30). Unnecessary use of broad-spectrum antibiotics might contribute to the 
development of resistant bacteria or to adverse events such as toxicities and hypersensitivity 
reactions (31, 32). 
One way to improve the use of antibiotics and reduce the development of antibiotic resistance 
is to develop and implement guidelines for antibiotic prescribing (33). Jaggi et al. showed a 
significant decrease in carbapenem-resistant Pseudomonas after implementation of an 
antibiotic prescribing policy at an Indian hospital (34). Subsequently, further improvement was 
made when an antimicrobial stewardship committee was developed and implemented at the 
hospital, which resulted in a decrease of carbapenem-resistant Pseudomonas (34). In 2014, 
Chandy et al. reported on the distribution of brochures with revised guidelines for antibiotic 
prescribing at a hospital in India. The brochures could also be accessed through the hospital’s 
intranet. After these arrangements, the monthly use of antibiotics decreased by 37% (35). 
It is very important to have access to prescribing guidelines that are adapted to the latest reports 
of resistance and susceptibility in order to make good decisions for both empirical and targeted 
antibiotic prescribing (16, 23, 24). On a national level, there is a need for lists of essential 
medicines and guidelines for the treatment of community-acquired and health-care-associated 
infections, which can provide a base for local prescribing guidelines and education at hospitals 
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and local health centres. This could contribute to reducing the unnecessary prescribing of 
broad-spectrum antibiotics, limit the development of antibiotic resistance, improve public 
health, improve patients’ health outcomes, avoid adverse events and possibly reduce the 
pressure on health-care services (16). The WHO produces many lists of essential medicines, 
including antibiotics, which can be used as a guide for the development of local antibiotic 
prescribing guidelines (36). The guidelines should be adapted for available resources and 
developed for targeted interventions to implement then at a local level (37).  
1.2.2 Antibiotic use in India 
Historically, access to antibiotic treatment has been limited or absent in many LMICs, 
including India (15, 38). However, recent studies of antibiotic use in India have shown that the 
consumption of antibiotics is high and increasing, both in private and public health care, since 
the access to antibiotics has increased (33). There are associations between high domestic 
production of antibiotics, rising incomes, lower costs of antibiotics, lack of control of antibiotic 
use in health care, informal health-care providers, over-the-counter sales of antibiotics and 
rising consumption of antibiotics in LMICs, especially in India (38-41). Informal health-care 
providers–those without a formal degree in medicine who are not registered as health-care 
practitioners–are common in resource-limited settings where the health-care systems are weak 
(42). In rural India, these informal health-care providers, which include unqualified doctors, 
spiritual healers, unqualified medicine vendors and traditional birth attendants, constitute more 
than 50% of all active health-care providers (42-45). Khare et al. collected prescriptions from 
12 informal health-care providers in rural India over 18 months and found that 74% of the 
prescriptions included antibiotics and 95% of antibiotics prescribed were of broad-spectrum 
types, indicating that there is a need for interventions to reduce unnecessary prescribing of 
antibiotics among such informal health-care providers (39). Supporting this, Mohanta et al. 
showed that there are extensive needs regarding the improvement of private sector health care 
in India, where uncontrolled antibiotic prescribing is common, and antibiotics can often be 
bought over the counter without prescriptions (46). It has been stated that the consumption of 
broad-spectrum antibiotics is common in India and that there are needs for improvements to 
rationalize antibiotic prescribing practices (47). Further, fixed-dose combinations (FDCs) of 
antibiotics are commonly prescribed in India, although not recommended because FDCs have 
been shown to drive antibiotic resistance, contributing to further unnecessary use (48). 
Antibiotic dosage should be tailored for the individual patient, which is often not possible while 
prescribing FDCs. Some FDCs, including unapproved formulations, are known to be used 
widely in India (49-52). In 2016, the Indian Government banned approximately 330 FDCs, of 
which 19% included antibiotics (53). Nevertheless, there are more than 118 FDCs of antibiotics 
available on the Indian market (53). 
To analyse the prescribing of antibiotics can be difficult, depending on how the health-care 
system is structured. In India, patient records might not be computerized, so data collection and 
mapping of antibiotic use can be difficult (22). It has also been shown that there are difficulties 
in mapping resistance and susceptibility patterns because in many areas, samples are not sent 
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for culture on a regular basis (22, 33). To be able to use effective and sustainable treatments 
now and in the future, there is a need to focus on actual antibiotic prescribing practices and on 
the development and implementation of diagnostic methods for better management of 
infectious diseases in resource-limited settings. 
1.3 INFECTIOUS DISEASES 
Previous studies from India have shown that critically ill patients, such as patients in intensive 
care units (ICUs) and patients with a high suspicion of infectious causes of illness–for instance 
children–are often prescribed antibiotics although they might not have a relevant indication for 
such treatment (16, 28, 54). According to guidelines, antibiotics should only be prescribed to 
patients with an infection, or in certain cases for the prevention of one (16, 23, 24). These 
guidelines are often based on the site of infection, and/or which bacteria have caused the 
infection, and their susceptibility patterns. This can be difficult in settings with limited access 
to diagnostic methods, where the diagnoses for which the patients are prescribed antibiotics are 
often based on clinical suspicion rather than being verified by diagnostic procedures (4, 22, 
35). Symptomatic management of a suspected infection using antibiotic treatment can be 
effective, but can also result in overuse and potential risks for the development of antibiotic 
resistance (55, 56). The lack of access to diagnostic methods in resource-limited settings is a 
major obstacle to combatting infectious diseases (57). When access to diagnostic methods is 
lacking, the risk of disregarding important infections that require rapid and extensive antibiotic 
treatment increases (58). Life-threatening infections such as sepsis, pneumonia and IE can be 
overlooked without diagnostics, which can lead to devastating consequences for the patient 
(59, 60). 
1.3.1 Infective endocarditis 
This is a severe infectious disease that can be fatal rapidly if not found and treated properly 
(60, 61). According to the Global Burden of Disease study of 2017, IE was associated with 
2.23 million disability-adjusted life-years (DALYs; 1 DALY represents the loss of the 
equivalent of 1 year of full health), as a result of death, nonfatal illness or impairment (62). The 
global changes in DALYs were measured between 2007 and 2017, and decreased among many 
infectious diseases (for instance lower respiratory tract infections (RTIs), tuberculosis, sexually 
transmitted infections, enteric infections and meningitis); however, a 17.1% increase in 
DALYs was seen for IE (62). IE has been shown to be one of the four most common life-
threatening infections, together with sepsis, pneumonia and intra-abdominal abscess (63). 
IE can cause heart valve destruction, perivalvular abscesses, aneurysms and fistulas, and it is 
therefore of great importance to diagnose it and initiate antibiotic treatment quickly to avoid 
the progression of such manifestations (64, 65). Microbiological analysis is important in the 
diagnostics because most patients with IE present with bacteraemia. The bacterial species 
causing bacteraemia is considered the most probable cause of IE. However, a positive blood 
culture is not sufficient for a definitive diagnosis of IE (64, 66). This should be based on 
modified Duke criteria (Table 1) and defined as definite or possible IE depending on clinical 
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or pathological fulfilment of the major or the minor criteria (64, 67). For definite IE, two major 
criteria, or one major criterion and three minor criteria, or five minor criteria should be present. 
For possible IE, one major and one minor, or three minor criteria should be present (64, 67, 
68). 
Table 1. The modified Duke criteria for the diagnosis of infective endocarditis (IE) 
Major 
criteria 
Blood cultures positive for IE 
Typical microorganisms consistent with IE from two separate blood cultures 
or 
Microorganisms consistent with IE from persistently positive blood cultures 
or 
Single positive blood culture for Coxiella burnetii or phase I IgG antibody titre > 1:800 
Evidence of endocardial involvement 
ECHO positive for IE (vegetation, abscesses, new partial dehiscence of a prosthetic valve) 
New valvular regurgitation 
Minor 
criteria 
Predisposition (heart condition or injection drug use) 
Fever (temperature >38 oC) 
Vascular phenomena (detected by imaging such as major arterial emboli, septic pulmonary infarcts, 
infectious aneurysms, intracranial haemorrhage, conjunctival haemorrhages, Janeway’s lesions) 
Immunological phenomena (glomerulonephritis, Osler’s nodes, Roth’s spots, rheumatoid factor) 
Microbiological evidence (positive blood culture not meeting a major criterion or serological evidence of 
active infection with organisms consistent with IE) 
Adapted from (64, 67).  
IE requires long antibiotic treatments: 2-6 weeks for native valve IE depending on the causative 
bacteria and manifestations, and at least 6 weeks for prosthetic valve IE (68, 69). International 
guidelines for the management of IE suggest that empirical antibiotic treatment is appropriate 
when IE is suspected, that bactericidal treatment should be used rather than bacteriostatic, and 
that surgical treatment for IE should be performed when necessary (64). 
Clinical and microbiological data of IE from resource-limited settings are scarce, and the 
disease is commonly underdiagnosed (70-72). Few studies have been conducted, these have 
shown that the mortality among patients with IE is higher in LMICs compared with high-
income countries, with mortality rates of almost 30% (73, 74). Factors contributing to the high 
mortality rates can be limited diagnostic methods and access to surgical treatment for IE in 
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resource-limited settings; moreover patients might seek health care late after the onset of IE 
(61, 73). A major risk factor for IE in LMICs is rheumatic heart disease (RHD), a complication 
of rheumatic fever affecting the heart valves (74). In high-income countries, RHD has almost 
disappeared but it is still a problem in many LMICs, contributing to high rates of disability and 
over a million premature deaths annually (75, 76). India contributes to about 25–50% of the 
global burden of RHD, indicating that there are many people at increased risk of developing IE 
in that country (70, 71, 74). However, a study from India also noted that underdiagnosing of IE 
is a considerable problem (77), indicating that the diagnosis and management of IE in India as 
well as in other LMICs need to be improved. 
1.4 DIAGNOSTICS 
To be able to successfully manage infectious diseases and rationalize antibiotic use, there is a 
need to focus on the development and implementation of diagnostic methods for identifying 
infectious foci, and verifying pathogens and their resistance patterns (16). In resource-limited 
settings, access to diagnostic methods can be limited or absent and antibiotics are often 
prescribed empirically, based on a clinical suspicion of infection (4, 16, 27, 28). Further, limited 
access to diagnostic methods increases the risk of underdiagnosing infections, which might 
lead to ineffective treatment. 
1.4.1 Microbiological analyses 
Diagnostic information about the pathogen that caused the infection is a prerequisite to 
prescribing a targeted antibiotic treatment for IE. The most common method to identify the 
pathogen is to send samples for culture, which requires access to a laboratory for 
microbiological analyses (20). However, results from such analyses usually take a few days, 
which might cause delays in initiating treatment; this can be associated with increased 
mortality. Therefore, broad-spectrum antibiotics are often prescribed empirically, while 
awaiting the response from microbiological analysis, even though it is known that 
overprescribing of broad-spectrum antibiotics drives antibiotic resistance (7). It is a major 
challenge to prescribe antibiotics rationally. A study from the USA has shown that clinicians 
consider that the proper empirical prescribing of antibiotics is difficult if guidelines for 
treatment pathways do not give explicit recommendations (78). These perceived difficulties 
arise because recommendations are often written for infections with known bacteria, or because 
the guidelines are not adapted to local resistance patterns (18, 78). To be able to follow such 
guidelines, access to microbiological analyses and data on individual pathogen susceptibility 
to different antibiotics from locally performed blood cultures is necessary and susceptibility 
tests are required (18). Another obstacle is that prescribers must take the results from the 
microbiological analysis into account, which is not always done. It is crucial to educate 
prescribers about the importance of these results, because it can guide treatment and help 
reduce the unnecessary use of antibiotics (20, 79). 
 8 
1.4.2 Imaging 
In combination with microbiological analysis, diagnostic imaging methods are often 
recommended to verify the site and manifestations of some infections and can also be used for 
follow-ups. Depending on the suspected site of infection and the clinical evaluation of the 
patient, a variety of imaging techniques can be used. In resource-limited settings, access to 
imaging diagnostics might be limited or absent, because such methods can be costly and labour 
intensive (80). However, ultrasonography can provide a rapid diagnosis; it does not expose the 
patient or personnel to ionizing radiation, it can be portable and it requires less training 
compared with computed tomography and magnetic resonance imaging (80). Therefore, the 
WHO has pointed out the advantages of ultrasonography in LMICs, which have been 
confirmed by studies describing its successful use in resource-limited areas (81-84). 
Ultrasonography can be used to assess infectious processes such as abscesses and fistulas, and 
echocardiography (ECHO) is suitable for the assessment of cardiac diseases such as IE (64, 65, 
85). 
In 2019, Murphy et al. published a comparative review of the most recently available guidelines 
for the management of IE by the Task Force for the Management of IE of the European Society 
of Cardiology and the American Heart Association IE Writing Committee, (64, 66, 86). The 
review focusses on the role of imaging in the evaluation and management of patients with IE, 
and presented conclusive recommendations for the initial assessment of patients with clinically 
suspected IE using ECHO (86). ECHO can be used to identify one or more of the typical 
manifestations of IE such as vegetation, abscesses, aneurysms, destruction and fistulas (64). 
Figure 1 shows normal mitral and aortic valve morphology compared with mitral valve 
vegetation and aortic valve vegetation and destruction. ECHO can be conducted using a 
transoesophageal (TEE) or a transthoracic (TTE) approach, but the TEE method often provides 
better image quality, which increases the chance of finding infections. Microbiological analysis 
is an important step to advance the diagnosis of a patient with suspected IE. However, a positive 
culture confirming bacteraemia in itself is not enough to confirm this (64, 69). To confirm the 
diagnosis, one or more infectious manifestations need to be verified by ECHO, and many 
hospitals use this in daily clinical work, together with microbiological analysis to identify and 
diagnose IE (64, 65, 68). It should be noted that according to international guidelines for the 
treatment of IE, antibiotic treatment is recommended if manifestations of IE are found on 
ECHO, and also if the results from microbiological analyses of blood samples are negative (64, 
65, 87). Identification of aetiology and cardiac IE manifestations are both crucial for the 
diagnosis and treatment of IE, yet the associations between microbiological data and ECHO 
findings need to be further explored (88-90). 
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Figure 1. Normal mitral and aortic valve morphology compared with mitral valve 
vegetation and aortic valve vegetation and destruction. A. shows normal mitral and aortic 
valves. B. shows vegetation on the mitral valve (yellow arrow) and vegetation and valvular 
destruction on the aortic valve (white arrow) caused by coagulase-negative staphylococci 
detected by transoesophageal echocardiography.  
1.5 THESIS RATIONALE 
To ensure long-term, successful prevention and treatment of infectious diseases and to retain 
antibiotics as available, effective and safe treatments with quality-assured medications, the 
WHO Global Action Plan on antimicrobial resistance requests all Member States to “monitor 
and promote optimization of antimicrobial use at national and local levels” (10). The aims of 
monitoring and promotion are to assess how antibiotics are being used by understanding when, 
how and why antibiotics are used irrationally, to improve the practices of antibiotic prescribers, 
dispensers and consumers, to assess the impact of interventions aiming to improve antibiotic 
use and to understand the relationship between antibiotic use and the spread of antibiotic 
resistance. 
In resource-limited settings, the burdens of infectious diseases and antibiotic resistance are both 
high. Today, the irrational use of antibiotics as well as the underdiagnosis of infections are 
common in resource-limited settings in India, contributing to unnecessarily high mortality rates 
from infectious diseases and to antibiotic resistance (38, 40, 41). To combat the burden of 
infectious diseases, the rational use of antibiotics and management of infectious diseases is 
required. To rationalize antibiotic use, it is necessary to map antibiotic prescribing practices 
and to identify areas for improvements. Historically, this has been difficult in resource-limited 
settings, as the economic conditions for health care are often low and patient records might not 
be computerized; hence data collection and mapping of antibiotic use can be challenging (22). 
By monitoring antibiotic use in a resource-limited setting in India, needs for improvements can 
be identified and provide the basis for future interventions.  
The challenges to appropriate use of antibiotics in resource-limited settings is aggravated by 
the lack or absence of diagnostic tools to assist clinicians in their clinical decision-making (91). 
There is a need to highlight the importance of diagnostic methods that can be used for 
identification and verification of infectious diseases in resource-limited settings. Diagnostic 
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methods can contribute with aspects such as individual evaluation of the disease and 
identification of complications which might be valuable for the clinicians in the management 
and treatment of patients with infectious diseases. Evaluating diagnostic methods that can be 
implemented and used in resource-limited settings is a way to get closer to optimized 
management and treatment of patients with infectious diseases in such settings. Initial 
evaluation of a diagnostic method in a high-income setting, where the method is fully 
implemented and of good quality, enables safe evaluation before implementation in resource-
limited settings.  
In areas with lack of access to diagnostics, there is a risk of underdiagnosing infectious diseases. 
IE is often underdiagnosed in such settings. Evaluating the significance of ECHO for the 
diagnosis of IE in a high-income setting, can be valuable for the implementation of ECHO and 
the management of patients with IE in resource-limited settings. 
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2 AIMS 
The overall aims of Papers I-III were to map and describe antibiotic prescribing practices for 
in-patients with infectious diseases in a resource-limited setting in India. A further aim of 
Papers I-III was to identify areas of improvements in the antibiotic prescribing practices and 
management of infectious diseases in such settings. Limited access to diagnostic methods 
complicates the management of infectious diseases in resource-limited settings and increases 
the risk of disregarding severe infectious diseases, such as IE. Therefore, it is important to 
evaluate diagnostic methods that can improve the management of infectious diseases in such 
settings. Paper IV focuses on analysing ECHO as a diagnostic method for IE. The aim was to 
assess whether specific manifestations detected by ECHO were associated with certain 
bacterial species in patients with IE, to evaluate whether the ECHO findings could give a 
suggestion of the bacterial aetiology in these patients. The findings could add aspects to the 
management and treatment of patients with IE. Paper IV was conducted in a high-income 
setting in Sweden, where a national registry of patients with IE was available, and where both 
microbiological analyses and ECHO were performed. The findings could possibly be useful 
also in resource-limited settings. 
The specific aims were as follows: 
 To describe and compare antibiotic prescribing practices in the medical ICUs (Paper 
I) and the paediatric departments (Paper II) respectively, at two hospitals in a resource-
limited setting in India. 
 To present the antibiotic prescribing practices among in-patients with severe infections 
over a 10-year period at two hospitals in a resource-limited setting in India (Paper III). 
 To evaluate associations between specific IE manifestations detected by ECHO, and 
bacterial species in patients with IE in a high-income setting in Sweden (Paper IV). 
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3 METHODS 
3.1 STUDY SETTINGS 
3.1.1 Ujjain 
Papers I–III are based on studies conducted in the Ujjain district of Madhya Pradesh, India 
(Figure 2). This district has approximately 2 million inhabitants, of whom approximately 61% 
live in rural areas and villages (92). Madhya Pradesh is less economically and socially 
developed, with lower health-care performance and higher infant and maternal mortality, than 
many other states of India. In 2017, India had an overall infant mortality rate (death before the 
age of 1 year) of 36 per 1000 reported live births, and Madhya Pradesh had an infant mortality 
rate of 41.9. The infant mortality rate in the Ujjain district was 28.7 (93, 94). The predominant 
risk factors for infant mortality in Madhya Pradesh and Ujjain are child and maternal 
malnutrition (93). In India, the number of years of healthy life expectancy in 2016, which 
corresponds to the number of years a person is expected to continue to live in a healthy 
condition at birth, was 59.9 years for women and 58.7 years for men (95). In 2011, the 
calculated number of hospital beds per 10,000 people in India was 7 (for reference, globally 
the number of hospital beds per 10,000 people in 2011 was 27) (96). 
 
Figure 2. Map of India (yellow), Madhya Pradesh (red) and the Ujjain district (black). 
The studies were conducted in two tertiary care, private sector hospitals run by the same 
charitable trust, a non-teaching hospital (NTH) and a teaching hospital (TH). When Paper I 
and II were conducted, the NTH had 350 beds and the TH had 570 beds. When Paper III was 
conducted, the NTH had 400 beds and the TH had 800 beds. The NTH is located centrally in 
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Ujjain city while the TH is located in a rural area of the Ujjain district. At the NTH, medical 
services are charged but at a reduced level and the patients must also purchase their medicines 
during hospital stay. At the TH, patients are provided with medical services and medicines free 
of charge. Representatives from pharmaceutical companies can visit the prescribers at the NTH 
but not at the TH. At the time when the data was collected (2008–2017), no local prescribing 
guidelines were available at the hospitals; however, a local essential medicines list was 
available at the TH, although it was not implemented completely. Samples were not sent 
routinely for microbiological analyses (culture) at either of the hospitals and diagnostic imaging 
methods were limited. 
3.1.2 Stockholm 
Paper IV is based on data from patients admitted to the Karolinska University Hospital (KUH) 
in Stockholm, Sweden. On 31 March 2020, Stockholm county had a population of 
approximately 2.4 million (97). The estimated infant mortality rate in Stockholm county was 
1.9 deaths per 1000 live births in 2017 (98). By comparison, the overall infant mortality rate in 
Sweden was 2.1 deaths per 1000 live births in 2019 (99). In 2016, Sweden had the greatest 
number of healthy years of life expectancy among the European countries (73.3 years for 
women and 73.0 years for men) (100). There were 26 hospital beds per 10,000 people in 
Sweden in 2013 (96). 
The study was conducted at the KUH in Stockholm, which is one of the largest university 
hospitals in Europe (101). Here, both ECHO and microbiological analysis are used routinely 
among patients with IE and both techniques are of high quality. There is a Department of 
Clinical Physiology specialized in cardiac imaging with a large focus on the latest technology 
in ECHO. In compliance with guidelines for the management of IE, there is a multidisciplinary 
team of physicians from the departments of Infectious Diseases, Clinical Physiology, 
Cardiology, and Thoracic Surgery that manage the patients with definite or possible IE (64). 
3.2 OVERVIEW OF PAPERS 
An overview of the papers arising from this thesis is presented in Table 2. 
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Table 2. Overview of papers and methods 
Paper I II III IV 
Topic AB prescribing in 
intensive care units 
AB prescribing in 
paediatric departments 
Empirical AB prescribing 
to patients with severe 
infections in 2008–2017 
Associations between 
ECHO manifestations 
and bacteria in 
patients with IE 
Design Prospective cross-
sectional study 
Prospective cross-
sectional study 
Time series analysis Registry-based cohort 
study 
Data 
sources 
Data collection from 
the NTH and TH in 
Ujjain 
Data collection from the 
NTH and TH in Ujjain 
Data collection from the 
NTH and TH in Ujjain 
Swedish National 
Registry of Infective 
Endocarditis 
Study 
population 
In-patients at medical 
ICUs (all ages) 
4,843 patients 
In-patients at paediatric 
departments (<18 years) 
6,993 patients 
In-patients (>18 years) 
with severe infectious 
diseases 
3,766 patients 
In-patients (>18 years) 
with definite IE at 
KUH, Stockholm 
492 patients 
Study 
period  
1 April 2008 to 31 
March 2011 
1 April 2008 to 31 
March 2011 
1 April 2008 to 31 May 
2017 
1 Jan 2008 to 31 Dec 
2017 
Exposure  Any infectious 
diagnosis or 
presumed symptoms 
of infection or no 
infectious diagnosis 
Acute gastroenteritis, 
respiratory tract 
infections, enteric fever, 
viral or unspecified 
fever 
Epiglottitis, pneumonia, 
peritonitis, pyelonephritis, 
cellulitis, erysipelas, septic 
arthritis, IE, meningitis, 
sepsis 
Bacteria found in 
blood culture or 
culture/PCR from 
surgical material 
Covariates Age, sex, at the TH 
or NTH 
Age, sex, at the TH or 
NTH 
Year of AB prescription at 
the TH or NTH 
Native versus 
prosthetic valves, IV 
drug abuse, bicuspid 
aortic valve 
Outcomes AB prescription AB prescription AB prescription IE manifestations 
detected by ECHO 
Main 
statistical 
analyses 
Chi-squared test, 
Student’s t test 
Chi-squared test, 
Student’s t test 
Linear regression, chi-
squared test 
Logistic and linear 
regression, Student’s t 
test, chi-squared test 
AB, antibiotic; ECHO, echocardiography; ICU, intensive care unit; IE, infective endocarditis; IV, intravenous; KUH, 
Karolinska University Hospital; NTH, non-teaching hospital; PCR, polymerase chain reaction; TH, teaching hospital. 
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3.3 DATA SOURCES 
3.3.1 Data of patients at the NTH and the TH in Ujjain 
For Papers I-III, patient data were collected manually from the NTH and the TH in Ujjain by 
specially trained nursing staff. Neither of the hospitals had computerized prescribing records. 
A form was developed to record antibiotic prescribing for each patient at the hospitals. This 
was attached to each patient’s file at admission to the hospital and was updated daily until 
discharge from hospital or death. The form included the patient’s age, sex, department number, 
registered diagnoses and dates for admission and discharge. If antibiotics were prescribed, the 
form included what antibiotic had been prescribed with its generic and trade name, route of 
administration, dose, frequency and date of prescription. To minimize the risk of missing data, 
the form was printed on pink paper to be visible among others in the patient’s file. As of 2008, 
data from the forms were entered to a file by trained computer operators. 
For Paper I, all patients admitted to the medical ICUs at either the NTH or TH who stayed at 
least one night in hospital between 1 April 2008 and 31 March 2011 were included. At the 
NTH there was a separate ICU for neonatal patients, who were not included in the study. At 
the TH, there were separate ICUs for medical patients, surgical patients, paediatric patients and 
neonatal patients. In this study, only data for the patients from the medical ICU were included. 
Some paediatric patients were admitted to the medical ICU, so were included. Of the 6,141 
patients admitted to the medical ICUs (4,338 from the NTH and 1,803 from the TH), 4,843 
were included, 3,472 from the NTH and 1,371 from the TH. 
For Paper II, all patients younger than 18 years of age who stayed for at least one night at 
either of the paediatric departments at the NTH or the TH between 1 April 2008 and 31 March 
2011 were analysed. Of the 6,825 patients admitted to the paediatric departments during this 
period, 4,848 from the NTH and 1,977 from the TH were included. 
For Paper III, data were included for patients aged 18 years and older, admitted to the NTH 
and the TH between 1 April 2008 and 31 March 2017 and who stayed at least one night, with 
one of the following diagnoses (which the WHO lists as indications for empirical treatment): 
epiglottitis, pneumonia, peritonitis, pyelonephritis, cellulitis, erysipelas, septic arthritis, IE, 
meningitis and sepsis (25). Of the 243,774 patients admitted to the hospitals during this period 
(134,666 from the NTH and 109,108 from the TH), 3,766 were included: 2,504 from the NTH 
and 1,262 from the TH. 
3.3.2 Swedish National Registry of Infective Endocarditis 
For Paper IV, data was obtained from the Swedish National Registry of Infective Endocarditis 
(SRIE), which was established in 1995. Since 2008, data from patients treated for definite or 
possible IE (International Classification of Diseases codes I33.0, I33.9, I38.9 and I39.8) has 
been reported online by all Swedish departments for infectious diseases. The SRIE’s coverage 
for patients with IE is estimated to be 85% (when compared with the Swedish health-care 
statistics network of registered diagnoses in 2016) (102). Data in the registry include age, sex, 
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results from blood cultures, and/or polymerase chain reaction (PCR) amplification results from 
material obtained during cardiac surgery, ECHO findings, whether antibiotics had been 
prescribed, duration of antibiotic treatment, in-hospital mortality (defined as death during 
hospital stay) as well as risk factors such as intravenous (IV) drug abuse, and the presence of 
prosthetic cardiac or bicuspid aortic valves. 
Data from 593 patients at the age of 18 years or older, admitted to the Department of Infectious 
Diseases at the KUH with definite IE between 1 January 2008 and 31 December 2017 were 
obtained from the SRIE. Patients with both negative blood cultures and negative cultures from 
material obtained during cardiac surgery for IE were excluded, as were patients who did not 
undergo ECHO during hospital stay. In total, 492 patients with a definite diagnosis of IE were 
included in the study. 
3.4 METHODOLOGY FOR CLASSIFICATION OF ANTIBIOTICS 
For Papers I-III, the antibiotics were classified by generic names and the Anatomical 
Therapeutic Chemical (ATC) classification system and antibiotic prescribing was measured by 
calculating defined daily doses (DDDs) according to the WHO Collaborating Centre for Drug 
Statistics Methodology (WHOCC) (103). The purpose of using the ATC/DDD methodology 
was to monitor the prescribing or use of medicines effectively, and to combine and compare 
different substances. By using this internationally recognized method, medicine prescribing 
can be compared between different centres, both at local and international levels, and it is 
possible to study time trends in the use of a specific medicine. The ATC system classifies 
antibiotics into several subcategories, and for each substance there is a given DDD that 
corresponds to the assumed daily maintenance dose if a medicine is used for its main indication 
in adults (Table 3). DDD is used as a measurement to compare the exposure or therapeutic 
intensity of a medicine in a defined population between different time periods or between 
different population groups (103). 
The ATC/DDD methodology includes most of the medicines available on the market and is 
often updated for new medicines being developed and marketed. During the course of the 
thesis, the list of codes was updated, and it now contains several FDCs of antibiotics, that were 
not registered in the system at the time of the first two studies. For FDCs of antibiotics where 
no ATC codes were available, the codes were generated based on advice from the WHOCC 
(28). According to the WHOCC, oral metronidazole is coded as an anti-protozoal (P01) agent 
(103), but according to the National List of Essential Medicines in India (NLEMI), oral 
metronidazole is considered as an antibacterial for anaerobic infections (104). Thus, for Papers 
I and II, in which the antibiotic prescribing was related to the adherence for NLEMI, oral 
metronidazole was analysed as an anti-infective agent (J01) although it was coded as P01AB01 
(104). 
To preserve the effectiveness of antibiotic treatment and improve clinical outcomes, the WHO 
has adopted a classification of antibiotics that suggests how their use should be prioritized: the 
so-called access-, watch- and reserve antibiotic categories (10, 25, 36). Access antibiotics (first-
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line antibiotics) should be widely available, affordable and of good quality; watch antibiotics 
(second-line antibiotics) include most of the highest priority, critically important medicines and 
should be used only for specific and limited indications; and reserve antibiotics (third-line 
antibiotics) should only be used when all alternative antibiotics have been shown to be 
unsuccessful (10, 25, 36). 
Table 3. Example of classification of an antibiotic according to the ATC/DDD 
classification methodology 
Group J Anti-infectives for systemic use 
Subgroups J01 Antibacterials for systemic use 
J01M Quinolone antibacterials 
J01MA Fluoroquinolones 
ATC code J01MA02 Ciprofloxacin, 
DDD oral: 1 g 
DDD parenteral: 0.8 g 
Adapted from (103). For antibiotic classification, the 2019 ATC/DDD classification was used. ATC, Anatomical Therapeutic 
Chemical; DDD, defined daily dose. 
3.5 DATA ANALYSIS 
3.5.1 Paper I – Antibiotic prescribing in intensive care units 
All included patients were divided into three groups at each hospital according to their 
registered diagnosis: group 1, patients with registered infectious diagnoses; group 2, patients 
with diagnoses with presumed symptoms of infections, i.e. not registered with any infectious 
diagnosis but with symptoms of infections, for example fever; and group 3, patients registered 
with diagnoses not associated with infection. Patient data were analysed for age (divided into 
four age groups), sex, duration of hospital stay and whether antibiotics were prescribed during 
their hospital stay. The antibiotic prescription data were analysed for type of antibiotic, dose, 
treatment duration, frequency and route of administration and and–if it was prescribed–by 
generic or trade name. The total numbers of DDDs for prescribed antibiotics were calculated 
and compared. In addition, adherence to the WHO List of Essential Medicines (WHOLEM) 
and to NLEMI were evaluated.  
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3.5.2 Paper II – Antibiotic prescribing in paediatric departments 
Among all paediatric patients, the five most common diagnoses related to infectious diseases–
or to symptoms commonly associated with infectious diseases–were calculated. The patients 
were divided into five groups according to the most commonly registered infection-related 
diagnoses: acute gastroenteritis including bloody diarrhoea; RTIs including both upper and 
lower RTIs, pneumonia and bronchitis; enteric fever; viral or unspecified fever. Patient data 
were analysed for sex, duration of hospital stay and whether antibiotics were prescribed during 
hospital stay. The antibiotic prescription data were analysed for type of antibiotic, dose, 
treatment duration, frequency and route of administration and whether the antibiotic was 
prescribed by generic or trade name as well as the total number of DDDs per prescribed 
antibiotic. The drug utilization 90% methodology was used to present the prescribing of 
antibiotics accounting for 90% of all antibiotics prescribed (105). Further, adherence to the 
Indian Academy of Paediatrics List of Essential Medicines (IAP-LEM) was evaluated (106). 
3.5.3 Paper III – Empiric antibiotic prescribing for severe infections in 2008–
2017 
The included patients were analysed at group level depending on their registered diagnosis: 
epiglottitis, pneumonia, peritonitis, pyelonephritis, cellulitis, erysipelas, septic arthritis, IE, 
meningitis and sepsis; however, few patients were registered with epiglottitis, pyelonephritis, 
erysipelas, septic arthritis, IE or meningitis, so data from patients with pneumonia, peritonitis, 
cellulitis and sepsis were selected for detailed analysis. Patient data were analysed for age, sex, 
duration of hospital stay and whether antibiotics were prescribed. The antibiotic prescription 
data were analysed for type of antibiotic, dose, treatment duration, frequency, number of 
prescriptions per patient as well as DDDs. The antibiotic prescribing was measured in DDDs 
per 1,000 patient days using the following formulae:  
DDD per prescription = dose in grams * frequency/WHO DDD for the prescribed antibiotic  
DDD per 1000 patient days = (DDDtotal * 1000/365)/N), 
where DDDtotal is the total antibiotic prescribing (in DDDs) prescribed during 1 year among a 
patient group and N is the total number of patients in that group during that year. 
For antibiotic classification, the 2019 ATC/DDD classification was used (103). Antibiotics 
were grouped according to the first 4–5 characters of their ATC code: J01A, J01B, J01C group 
1 (including all antibiotics in J01CA–J01CG), J01CR, J01D, J01E, J01F, J01G, J01M, J01R 
and J01X (Table 3). The antibiotics were also classified for: access, watch, reserve and FDCs 
of antibiotics according to the WHO (10, 25, 36). Some of the prescribed antibiotics were not 
categorized specifically by the WHO but if their antibiotic groups were classed, these 
antibiotics were added to the relevant category according to their antibiotic group. For example, 
cefuroxime was not categorized by the WHO, but second generation cephalosporins were 
categorized as access antibiotics, and because cefuroxime is a second generation 
cephalosporin, it was added to the access category for analysis (107). The following antibiotics 
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were added in the access category: first generation cephalosporins (cefadroxile, cefradine); 
second generation cephalosporins (cefuroxime, cefaclor); aminoglycosides (netilmicin, 
streptomycin, kanamycin, tobramycin); and ornidazole, tinidazole, piperacillin and 
tazobactam. For the watch category: third generation cephalosporins (cefoperazone, 
cefodoxime); quinolones and fluoroquinolones (ofloxacin, gemifloxacin, gatifloxacin, 
pazufloxacin, prulifloxacin); and finally the macrolid roxithromycin. Because the FDCs of 
antibiotics consist of at least two antibiotics, often from different categories, FDCs were added 
as a separate category (Appendix I). 
3.5.4 Paper IV – Associations between ECHO manifestations and bacteria in 
patients with IE  
The patients were divided into groups according to the bacteria registered as possible infectious 
pathogens causing IE in each patient. The primary pathogen was considered to be the bacterial 
strain identified from positive blood culture results, and the secondary pathogen was considered 
to be the bacterial strain cultured from material sampled during cardiac surgery or identified 
by PCR amplification. In total, 490 patients had positive blood culture results, and two patients 
had negative blood culture results but positive cultures or PCR amplification from material 
sampled during cardiac surgery; in total, 492 patients were included. Among patients with 
positive blood culture results, 19 were registered as having more than one bacterial species (or 
bacteria plus fungi); in such cases the first pathogen listed was chosen for analysis. Patient data 
were analysed for age, sex, bacterial pathogen causing the IE as explained above, any history 
of IV drug abuse, bicuspid aortic valve, prosthetic or native cardiac valve, surgical treatment 
for IE, in-hospital mortality as well as for the manifestations and total numbers of 
manifestations of IE detected by ECHO. The IE manifestations detected by ECHO were 
divided into groups depending on their location and morphology: aortic valve vegetation; 
mitral valve vegetation; tricuspid valve vegetation; pulmonary valve vegetation; cardiovascular 
implantable electronic device (CIED)-associated IE; ventricular septal defect; and perivalvular 
abscess. The manifestations were analysed both separately and together, among those patients 
with more than one registered ECHO manifestation. 
3.5.5 Statistical analyses 
Data were analysed using Stata version 13.0, 15.0 and 16.0 (Stata Corp., College Station, TX, 
USA), IBM SPSS statistics version 22.0 (IBM Corp., Armonk, NY, USA) and Excel 
(Microsoft Corp., Redmond, WA, USA). Descriptive analyses were conducted for all studies 
and are presented with frequencies and percentages for categorical variables and means and 
standard deviations (SDs) or medians and 25th and 75th percentiles for continuous variables. 
All statistical tests were two-tailed. 
For Papers I and II, chi-squared tests (for numbers > 5) and Fischer’s exact test (for numbers 
< 5) were used for comparing categorical variables. For Papers I and II, when comparing 
continuous variables, independent samples t tests were used because the variables were 
distributed normally at both hospitals. For Paper I, Bonferroni’s correction for multiple 
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comparisons was applied and an adjusted significance level of 0.001 was calculated, therefore, 
P values ≤ 0.001 were considered significant. For Paper II, P values < 0.05 were considered 
significant. 
For Paper III, linear regression was used for comparing continuous variables. For comparing 
categorical values, chi-squared tests (for values > 5) and Fischer’s exact test (for values < 5) 
were applied and the results were presented as odds ratios (ORs) and 95% confidence intervals 
(CIs). Time series analysis of antibiotic prescribing from 2008 to 2017 was performed by linear 
regression, with DDDs per 1,000 patient days as the dependent variable and the year as the 
independent variable, to obtain a slope for the trend. Time series analyses were conducted for 
the prescribing of antibiotics in the “access, watch, reserve, and FDCs of antibiotics” categories 
as well as for antibiotic prescribing among the five most common diagnoses: sepsis, cellulitis, 
pneumonia, peritonitis and meningitis. P values < 0.05 were considered significant. 
For Paper IV, logistic regression, chi-squared tests (for values > 5) and Fisher’s exact test (for 
values < 5) were conducted for comparing categorical values and are presented with ORs and 
95% CIs. Linear regression and Student’s t tests were used to compare continuous variables 
and skewed variables were log-transformed to normalize them before analyses. Linear and 
logistic regression analyses were used for multivariable analysis and linear regression was used 
for secular trend analysis.  P values < 0.05 were considered significant. 
3.6 ETHICAL CONSIDERATIONS 
Papers I-III include data from patients admitted to the two hospitals in Ujjain, India. Data 
from patients included in Papers I-III were collected by trained nurses at the two hospitals. 
The patients were informed about the research project at the time of admission to hospital. The 
form for data collection included information about whether the patient was prescribed 
antibiotics and, if so, information about the particular treatment. The forms from the hospitals 
were collected regularly by a person involved in the project and the information was entered to 
a computerized file. The forms were kept secure by the research group in Ujjain. Data were 
registered anonymously and since there were no personal identity numbers entered in the 
forms. For anonymizing, a unique code was given for each patient form with no possibility to 
track the data to an individual person’s identity. Hence, the studies are unlikely to harm the 
patients’ integrity. Because these studies were observational, they did not affect or cause any 
changes in the patients’ treatments and no additional examinations of the patients were 
conducted. 
Paper IV covers data from patients who attended the Department of Infectious Diseases at the 
KUH, obtained from the SRIE. The patients were informed about the registry during their 
hospital stay, and that the data might be used in further research. The study did not imply any 
risks for the patients because it did not affect or cause any changes in the patients’ treatments 
and no additional examinations of the patients were conducted. Ethical aspects that the study 
could implicate are primarily related to personal integrity and data security. Using data from 
the existing registry implies minimal risk for the included patients, and intrusion to personal 
 22 
integrity was eliminated by anonymizing the data. Data from the SRIE were obtained in 
anonymized form; this is possible without prior consent according to the Swedish Data 
Protection Authority (108). The risk of data dissemination was minimal because both ethical 
approval from the Regional Ethics Review Board and permission from the Registry Board of 
the SRIE were required to obtain and use the data from the SRIE. 
The studies did not directly benefit the included patients, but the study results might lead to 
improvements in the management of patients in the hospitals, both in Ujjain and in Stockholm. 
Presentation of the results from the studies in Ujjain could lead to improved practices and 
routines in antibiotic use and prescribing, and thus contribute to reducing the risk of 
development of antibiotic resistance. Presentation of the results from the study in Stockholm 
might lead to improvements in the management of patients with IE, possibly with faster 
diagnostics and shorter times to adequate antibiotic treatment. 
Papers I–III were approved by the Ethics Committee of Ruxmaniben Deepchand Gardi 
Medical College, Ujjain with approval numbers: 41/2007, 114/2010, and 311/2013, 
respectively. Paper IV was approved by the Regional Ethics Review Board, Stockholm, 
Sweden (number K 2018-6018). 
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4 MAIN RESULTS 
The main results of Papers I-IV have been integrated in this section, under appropriate 
headings. 
4.1 ANTIBIOTIC PRESCRIBING PRACTICES 
Table 4 shows the numbers of included patients, patients prescribed antibiotics and duration of 
hospital stay, and antibiotic treatment of patients from the medical ICUs (Paper I) from the 
paediatric departments (Paper II) and among patients registered with severe infections (Paper 
III) in the NTH and TH. 
Table 4. Antibiotic prescribing details at medical ICUs and paediatric departments at the 
NTH and TH in Ujjain, India 
 Paper I, medical ICUs 
Paper II, paediatric 
departments 
Paper III, patients with 
severe infections 
 
NTH TH P value NTH TH P value NTH TH P value 
Included patients, n (%) 
3472 
(100) 
1371 
(100)  
4848 
(100) 
1977 
(100)  
2504 
(100) 
1262 
(100) 
 
Female patients, n (%) 
1290 
(37) 
580 
(42)  
1418 
(29) 
842 
(43)  
894 
(36) 
301 
(24) 
 
Male patients, n (%) 
2182 
(63) 
791 
(58)  
3430 
(71) 
1135 
(57)  
1610 
(64) 
961 
(76) 
 
Patients prescribed 
antibiotics, n (%) 
2474 
(71) 
965 
(70) 0.548a 
3963 
(82) 
679 
(34) <0.001a 
2294 
(92) 
1122 
(89) <0.05a 
Female patients prescribed 
antibiotics, n (%) 
988 
(77) 
394 
(68) <0.001a 
1127 
(79) 
296 
(35) <0.001a 
809 
(90) 
259 
(86) 0.03a 
Male patients, prescribed 
antibiotics, n (%) 
1486 
(68) 
571 
(72) 0.033a 
2836 
(83) 
383 
(34) <0.001a 
1485 
(88) 
863 
(90) 0.03a 
Duration of hospital stay, 
mean days (±SD) 
2.6 
(3.1) 
4.9 
(5.9) <0.001b 
4.5 
(3) 
6.7 
(5.7) <0.001b 
4.4 
(4.8) 
10.1 
(10.5) <0.001b 
Duration of antibiotic 
treatment, mean days 
(±SD) 
3.2 
(2.5) 
4.9 
(4.3) <0.001b 
4.4 
(2.7) 
6.6 
(4.6) <0.001b 
1.1 
(0.35) 
9.4 
(8.9) <0.001b 
aP values were obtained using Pearson’s chi-squared test, comparing the distributions of patients prescribed antibiotics between 
the two hospitals. bP values were obtained from linear regression, comparing the mean days of hospital stay or antibiotic 
treatment duration between the two hospitals. Significant P values are shown in bold type. ICU, intensive care unit; NTH, non-
teaching hospital; SD, standard deviation; TH, teaching hospital. 
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Most of the patients registered with infection-related diagnoses at the medical ICUs were 
prescribed antibiotics at both hospitals (among patients with infections, 93% of the 400 at the 
NTH were prescribed antibiotics and 89% of the 189 at the TH, P = 0.030) (Paper I). Further, 
most patients in the medical ICUs with no infection-related diagnoses were prescribed 
antibiotics at both hospitals. Antibiotics were also prescribed to a high extent at both hospitals 
for presumed symptomatic reasons (Table 5). The most commonly prescribed antibiotics 
(comprising > 95% of all antibiotic prescriptions at either hospital) are presented in Table 6. 
Table 5. Antibiotic prescribing details at medical ICUs in the NTH and the TH in Ujjain, 
India (Paper I) 
Patient details NTH TH P valuea 
Patients with infections, n 400 189 0.030 
Patients with infections prescribed antibiotics, n (%) 373 (93) 168 (89) 0.071 
Patients with presumed symptoms of infections, n 319 151 <0.001 
Patients with presumed symptoms of infections prescribed antibiotics, n (%) 297 (93) 129 (85) 0.008 
Patients with diagnoses not associated with infections, n 2753 1031 <0.001 
Patients with diagnoses not associated with infections prescribed antibiotics, 
n (%) 1822 (66) 668 (65) 0.671 
Antibiotic prescription details NTH TH P valuea 
Total number of antibiotic prescriptions, n 10371 6647 
 
Antibiotic prescriptions by generic name, n (%) 272 (3) 733 (11) <0.001 
Antibiotic prescriptions by parenteral route 
of administration, n (%) 10081 (97) 5357 (81) <0.001 
Antibiotic prescriptions adherent to WHOLEM, n (%) 4847 (47) 3437 (52) <0.001 
Antibiotic prescriptions adherent to NLEMI, n (%) 5509 (53) 4654 (70) <0.001 
aP values were obtained using Pearson’s chi-squared test, comparing the distributions of patients or prescriptions between the 
two hospitals. Significant P values are shown in bold type. ICU, intensive care unit; n, number; NLEMI, National List of 
Essential Medicines in India; NTH, non-teaching hospital; SD, standard deviation; TH, teaching hospital; WHOLEM, World 
Health Organization List of Essential Medicines.  
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Table 6. The most commonly prescribed antibiotics at medical ICUs at the NTH and the 
TH in Ujjain, India (Paper I) 
ANTIBACTERIALS FOR SYSTEMIC USE: J01 NTH TH P valuea 
Tetracyclines: J01AA, n (%) 1 (0) 196 (3) <0.001 
Extended-spectrum penicillins: J01CA, n (%) 152 (1) 270 (4) <0.001 
Combination of penicillins including β-lactamase antibiotics: 
J01CR, n (%) 1963 (19) 1137 (17) 0.003 
3rd generation cephalosporins: J01DD, n (%) 2935 (28) 2096 (32) <0.001 
Carbapenems: J01DH, n (%) 176 (2) 2 (0) <0.001 
Other aminoglycosides: J01GB, n (%) 350 (3) 295 (4) <0.001 
Fluoroquinolones: J01MA, n (%) 512 (5) 1625 (24) <0.001 
Combination of antibiotics: J01RA, n (%) 3050 (29) 102 (2) <0.001 
Imidazole derivatives: J01XD, n (%) 877 (8) 703 (11) <0.001 
AGENTS AGAINST AMOEBIASIS & OTHER 
PROTOZOAL DISEASES: P01  
  
Nitroimidazole derivatives: P01AB, n (%) 2 (0) 170 (3) <0.001 
Total number of prescriptions, n 10371 6647  
aP-values were calculated using Pearson’s chi-squared test and Fischer’s exact test (for values <5), comparing the distribution 
of prescriptions between the two hospitals. Significant P values are shown in bold type. ICU, intensive care unit; NTH, non-
teaching hospital; TH, teaching hospital.  
4.2 FOCUS OF INFECTION 
Among patients in medical ICUs who were admitted to the NTH and TH from 2008 to 2011, 
400 (12%) of the 3,472 patients at the NTH and 189 (14%) of the 1,371 patients from the TH 
were registered with infectious diagnoses (I). The most common infectious diagnoses at the 
ICUs were gastrointestinal infections, meningitis, RTIs, sepsis, tuberculosis and urinary tract 
infections. Antibiotic prescribing rates and compliance with the WHOLEM and NLEMI 
among these patients are presented in Table 7. 
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Table 7. Antibiotic prescribing among patients with selected infections at medical ICUs 
in the NTH and the TH in Ujjain, India (Paper I) 
Diagnosis Patients, 
n (%) of patients prescribed 
antibiotics 
P 
valuea 
Antibiotic prescriptions, 
n (%) of prescriptions adherent to 
WHOLEM or NLEMI 
P 
valuea 
 NTH TH  NTH TH  
Gastrointestinal infections 33 (79) 36 (81) 0.855 89 (51) 192 (89) <0.001 
Meningitis 30 (100) 3 (100) - 135 (39) 60 (68) <0.001 
Respiratory tract infections 54 (96) 44 (93) 0.403 213 (31) 270 (30) 0.665 
Sepsis 93 (94) 10 (90) 0.522 417 (41) 56 (73) <0.001 
Tuberculosis 96 (96) 62 (89) 0.083 338 (58) 397 (62) 0.272 
Urinary tract infections 20 (100) 20 (90) 0.244 86 (52) 101 (75) 0.001 
aP-values were calculated using Pearson’s chi-squared test or Fischer’s exact test (for values <5), comparing the distribution of 
patients prescribed antibiotics or antibiotic prescriptions adherent to the WHOLEM or NLEMI, between the two hospitals. 
Significant P values are shown in bold type. ICU, intensive care unit; NLEMI, National List of Essential Medicines in India; 
NTH, non-teaching hospital; TH, teaching hospital; WHOLEM, World Health Organization List of Essential Medicines.  
Among the patients admitted to the paediatric departments in 2008–2011, the most common 
registered diagnoses related to infections were: acute gastroenteritis (including bloody 
diarrhoea), RTIs (including upper and lower respiratory tract infections, pneumonia and 
bronchitis), enteric, viral or unspecified fever (Paper II). Antibiotic prescribing rates and 
details in the diagnosis groups among paediatric patients are presented in Table 8 and the most 
commonly consumed antibiotics (measured in DDD per 1000 patients) are presented in Table 
9. Among the paediatric patients, less than 40% of the antibiotic prescriptions for paediatric 
patients were adherent to the Indian Academy of Paediatrics List of Essential Medicines (IAP-
LEM); adherence to the IAP-LEM was significantly higher at the TH compared with the NTH 
(prescriptions adherent to IAP-LEM: NTH 24% vs. TH 37%; P < 0.001). 
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Table 8. Antibiotic prescribing among paediatric patients with diagnoses related to 
infections in the NTH and TH in Ujjain, India (Paper II) 
Diagnosis Hospital 
Patients, 
n 
Patients 
prescribed 
AB, n (%) 
Duration of 
hospital stay, 
mean days 
(±SD) 
Duration of 
AB 
treatment, 
mean days 
(±SD) 
AB prescriptions, 
n (% prescribed 
by generic name) 
Number of 
different ABs 
prescribed in 
each diagnosis 
group, n 
GE 
NTH 925 695 (75) 3.55 (1.87) 3.50 (1.79) 3077 (5) 95 
TH 168 51 (30) 5.68 (4.33) 4.78 (2.30) 356 (64) 18 
P value    <0.001a <0.001b <0.001b <0.001a  
RTIs 
NTH 1017 940 (92) 4.40 (2.12) 4.32 (1.80) 5023 (2) 111 
TH 166 92 (55) 6.58 (4.67) 6.42 (3.67) 1039 (65) 27 
P value    <0.001a <0.001b <0.001b <0.001a  
Enteric 
fever 
NTH 218 205 (94) 4.79 (2.03) 4.75 (2.09) 1223 (1) 62 
TH 41 33 (80) 7.59 (4.25) 6.70 (2.02) 264 (74) 9 
P value    0.008 a <0.001b <0.001b <0.001a  
Viral 
fever 
NTH 185 130 (70) 3.86 (1.94) 3.76 (1.59) 532 (3) 53 
TH 101 32 (32) 5.87 (3.65) 5.27 (2.23) 212 (69) 17 
P value    <0.001a <0.001b 0.001b <0.001a  
Fever 
NTH 134 118 (88) 3.48 (1.43) 3.47 (1.48) 469 (1) 45 
TH 34 16 (47) 7.29 (6.31) 4.65 (3.25) 178 (77) 11 
P value 
 
 <0.001a 0.001b 0.127b <0.001a  
aP-values were calculated using Pearson’s chi-squared test, comparing the distribution of patients prescribed antibiotics or 
generic name antibiotic prescriptions, between the two hospitals. bP-values were calculated using Student’s t test, comparing 
the mean days of hospital stay or antibiotic treatment duration between the two hospitals. Significant P values are shown in 
bold type. AB, antibiotic; GE, gastroenteritis; NTH, non-teaching hospital; RTI, respiratory tract infections; TH, teaching 
hospital.  
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Table 9. DDDs prescribed per 1000 patients, accounting for 90% of the entire antibiotic 
prescribing within specific diagnosis groups at paediatric departments in the NTH and 
TH in Ujjain, India (Paper II) 
Antibiotic groups and subgroups GE RTIs 
Enteric 
fever Viral fever Fever 
  TH NTH TH NTH TH NTH TH NTH TH NTH 
ANTIBACTERIALS FOR SYSTEMIC USE: 
J01 886 1150 2301 2008 4746 4388 1019 1977 1832 2890 
β-lactam AB, penicillin: J01C 126 33 747 522 
 
225 117 63 447 73 
Extended-spectrum penicillins: J01CA 39 21 130 145 - 84 74 36 112 - 
Combination of penicillins including β-lactamase 
AB: J01CR 87 11 617 376 - 142 43 27 335 73 
Other β-lactams: J01D 437 402 849 477 4295 1536 736 1358 1156 1887 
2nd generation cephalosporins: J01DC - - - 125 - 211 - 605 - 1179 
3rd generation cephalosporins: J01DD 437 400 849 348 4295 1283 736 730 1156 707 
Aminoglycosides: J01G 237 160 463 58 300 94 155 21 228 45 
Other aminoglycosides: J01GB 237 160 463 58 300 94 155 21 228 45 
Quinolones: J01M 46 57 39 79 117 23 8 22 - - 
Fluoroquinolones: J01MA 46 57 39 79 117 23 8 22 - - 
Combination of ABs: J01R - 442 105 861 - 2465 - 506 - 886 
AB, antibiotic; DDD, defined daily doses; GE, gastroenteritis; NTH, non-teaching hospital; RTI, respiratory tract infections; 
TH, teaching hospital.  
Of all 243,790 patients admitted to the NTH and TH from 2008 to 2017, 3,766 (1.5%) were 
registered with cellulitis, IE, peritonitis, pneumonia, septic arthritis, epiglottitis, sepsis, 
meningitis or pyelonephritis (Paper III). Of these patients, 92% of those at the NTH and 89% 
of those at the TH were prescribed at least one antibiotic (Table 4). The most common 
diagnoses among patients with severe infections admitted to NTH and TH during the study 
period were cellulitis, peritonitis, pneumonia and sepsis, which comprised 88% of the included 
patients at NTH and 93% of the included patients at the TH (Paper III). Antibiotic groups 
comprising at least 75% of the total antibiotic prescribing among these diagnoses at each 
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hospital are presented in Appendix II. Antibiotics of the J01CR groups (combinations of 
penicillins including -lactamase inhibitors) and J01D (-lactam antibiotics) were among the 
most commonly prescribed antibiotics among all diagnosis groups at both hospitals. The total 
antibiotic prescribing over time is presented in Figure 3 and Table 10. Antibiotics included in 
the antibiotic groups are presented in Appendix II. 
 
Figure 3. Prescribing of antibiotics among patients with severe infections in the NTH and 
the TH in Ujjain, India, from 2008 to 2017 (Paper III). Prescribing is quantified and 
presented in DDDs per 1000 patients (y-axis) each year (x-axis) for selected infectious diseases 
for each hospital. Trends for each slope (see Table 10), indicating an overall positive or 
negative trend of antibiotic prescribing (measured in DDDs per 1000 patients), over the study 
period were obtained by linear regression analyses. DDD, defined daily dosis; NTH, non-
teaching hospital; TH, teaching hospital. 
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Table 10. Description of trends in antibiotic prescribing among patients with severe 
infections at the NTH and TH in Ujjain, India during 2008–2017 (Paper III) 
 NTH TH 
Antibiotic prescribing among specific diagnoses, ta (P valueb) 
All antibiotics 13.84 (<0.01) 1.82 (0.07) 
Cellulitis 5.72 (<0.01) 6.52 (<0.01) 
Peritonitis 14.59 (<0.01) 18.52 (<0.01) 
Pneumonia 4.87 (<0.01) 7.30 (<0.01) 
Sepsis 2.18 (0.03) -21.91 (<0.01) 
Antibiotic prescribing among all included patients, ta (P valueb) 
Access antibiotics 11.52 (<0.01) 1.78 (<0.07) 
Watch antibiotics 9.63 (<0.01) 6.49 (<0.01) 
Reserve antibiotics -0.76 (0.45) 2.54 (<0.01) 
FDCs of antibiotics 14.28 (<0.01) 7.31 (<0.01) 
Antibiotic prescribing among sepsis patients, ta (P valueb) 
Access antibiotics 1.49 (0.14) -16.89 (<0.01) 
Watch antibiotics 3.02 (<0.01) -11.38 (<0.01) 
Reserve antibiotics -9.32 (<0.01) Too few prescriptions 
FDCs of antibiotics 3.78 (<0.01) -9.93 (<0.01) 
at values were obtained by linear regression and indicate a positive or negative trend of antibiotic prescribing (measured in 
DDDs per 1000 patients), over the study period. A positive t shows a positive trend and a negative t shows a negative trend of 
prescribing. bP value were calculated using linear regression analysis, evaluating the difference (increase or decrease indicated 
by the slope) in antibiotic prescribing over the 10-year period. Statistically significant P values indicate significant trends and 
are shown in bold font. DDD, defined daily dose; FDC, fixed-dose combination; NTH, non-teaching hospital; TH, teaching 
hospital. 
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At the NTH, access antibiotics comprised 40% of the total antibiotic prescribing among 
patients with severe infections during 2008-2017; watch antibiotics 40%, reserve antibiotics < 
1% and FDCs of antibiotics 18%. At the TH, access antibiotics comprised 61% of the total 
antibiotic prescribing among patients with severe infections in 2008-2017, watch antibiotics 
29%, reserve antibiotics <1% and FDCs of antibiotics 8%. The prescribing of access, watch 
and FDCs of antibiotics increased from 2008 to 2017 at the NTH (P < 0.05) while at the TH, 
prescribing of watch, reserve and FDCs of antibiotics increased from 2008 to 2017 (P < 0.05 
respectively). The prescribing of access, watch, reserve and FDCs of antibiotics are presented 
in Figure 4 and Table 10.  
 
Figure 4. Prescribing of antibiotics categorized by access, watch, reserve and FDCs of 
antibiotics among patients with severe infections in the NTH and the TH in Ujjain, India, 
from 2008–2017 (Paper III). Prescribing is quantified and presented in DDDs per 1000 
patients (y-axis) each year (x-axis) of the total prescribing rate of each antibiotic category 
(access, watch, reserve and FDCs) for each hospital. Trends for each slope, indicating an 
overall positive or negative trend of antibiotic prescribing (measured in DDDs per 1000 
patients), over the study period were obtained by linear regression analysis. DDD, defined daily 
dose; FDC, fixed-dose combinations; NTH, non-teaching hospital; TH, teaching hospital.
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4.3 DIAGNOSTICS 
For Paper IV, data on 492 patients with definite IE (according to modified Duke criteria for 
IE) were obtained from the SRIE (64, 67). Clinical characteristics and predisposing factors of 
the included patients are presented in Table 11. 
Table 11. Descriptive data of patients with IE admitted to the Karolinska University 
Hospital in Stockholm, from 2008 to 2017 (Paper IV) 
All patients, n (%) 492 (100) 
Women, n (%) 161 (33) 
Men, n (%) 331 (67) 
Age, mean (± SD); medians (25th and 75th percentiles) 57.1 (18.4); 57 (44.5, 72) 
Predisposing factors 
History of IV drug abuse, n (%) 156 (32) 
Bicuspid aortic valve, n (%) 18 (4) 
Prosthetic valve, n (%) 92 (19) 
Cardiovascular implantable electronic device, n (%) 50 (10) 
Rheumatic heart disease, n (%) 2 (0) 
Congenital heart disease, n (%) 7 (1) 
History of IE, n (%) 78 (16) 
Known valvular disease, n (%) 75 (15) 
Heart failure before or during IE treatment, n (%) 60 (12) 
Clinical characteristics 
Fever, n (%) 432 (88) 
Vascular phenomena, n (%) 210 (43) 
New heart murmur, n (%) 77 (16) 
IE, infective endocarditis; IV, intravenous; SD, standard deviation. 
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There was no significant difference in mean age between male (56.8 years) and female patients 
(57.8, P = 0.58). The most common bacterial pathogens among the patients with IE were S. 
aureus, (239 patients, 49%), viridans group streptococci (102 patients, 21%) and E. faecalis 
(50 patients, 10%, Appendix III), and no gender differences in aetiology were found. In total, 
435 (88%) of the patients underwent TEE, 270 (56%) underwent both TTE and TEE and 57 
(12%) underwent TTE alone. In total, 409 patients (83%) had one IE manifestation and 83 
patients (17%) had more than one detected by ECHO. The distribution of IE manifestations 
detected by ECHO and bacterial aetiologies are presented in Appendix III. Bacterial aetiologies 
among patients with IE with IV drug abuse, prosthetic heart valves, prevalence of more than 
one IE manifestation, surgical treatment for IE, and patients with IE who died during hospital 
stay are presented in Appendix IV. The IE manifestations detected by ECHO among patients 
with IE with IV drug abuse, surgical treatment for IE and patients with IE that died during 
hospital stay are presented in Appendix V. 
Of the 239 patients with S. aureus aetiology, 122 (51%) had a history of IV drug abuse and 117 
(49%) did not. There was an association between S. aureus infection and tricuspid valve 
vegetation among patients with a history of IV drug abuse (OR 4.75; 95% CI 1.92–12.52; P < 
0.01) but not among patients who did not have IV drug abuse (OR 1.96, 95% CI 0.74–5.16; P 
= 0.12). 
Among patients with native aortic valves, the presence of aortic valve vegetation was 
significantly associated with findings of E. faecalis (OR 3.64; 95% CI 1.65–8.24; P < 0.01) and 
closely significantly associated with coagulase-negative staphylococci (CoNS) (OR 2.83; 95% 
CI 0.91–9.14; P = 0.04). However, there were no significant associations between aortic valve 
vegetation and E. faecalis (OR 0.67; 95% CI 0.20–2.36; P = 0.47) or CoNS (OR 3.89; 95% CI 
0.46–180.98; P = 0.18) respectively, among patients with prosthetic aortic valves. 
In our cohort, 92 patients (19%) had prosthetic heart valves, and 7 (8%) of these patients had 
two prosthetic heart valves. Patients with prosthetic heart valves were more likely to have E. 
faecalis-linked IE (Appendix IV). There was an association between the incidence of prosthetic 
heart valves and perivalvular abscesses (no specific locations were registered) (OR 17.64; 95% 
CI 6.89–50.34; P < 0.01). The described associations refer to the whole cohort of patients with 
prosthesis-associated IE in our study without differentiation between early- and late-onset IE, 
because this was not possible.  
In total, 139 (28%) patients were treated surgically. There was no difference in age between 
patients who did or did not undergo surgical treatment for IE (surgery mean age was 55 years, 
non-surgery mean age was 57.9 years; P = 0.12). There was no difference in surgical treatment 
between patients with prosthetic valve IE (n = 26) and patients with native valve IE (n = 113), 
(OR 1.00; 95% CI 0.58–1.69; P = 1.00). Patients with a history of IV drug abuse were treated 
less frequently with cardiac surgery (26 patients, 17%, OR 0.39; 95% CI 0.23–0.65; P < 0.01). 
There were no significant differences in in-hospital mortality between surgical (n = 12, 2%) 
and non-surgical treatment (n = 21, 4%; OR 1.49; 95% CI 0.65–3.29; P = 0.28). In patients 
presenting with an aortic root abscess, there was no significant association between surgical 
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treatment and in-hospital mortality (OR 0.75; 95% CI 0.07–11.07; P = 1.00), or between non-
surgical treatment and death (OR 1.33; 95% CI 0.09–4.58; P = 1.00). 
The overall in-hospital mortality was 7% (33 patients). There was an association between 
presence of perivalvular abscess and in-hospital mortality (n = 6; OR 4.21; 95% CI 1.29–11.81; 
P < 0.01, Appendix V). Among patients with S. aureus aetiology, in-hospital mortality was 
more common among left-sided valve IE (n = 14, 6%), compared with right-sided valve IE (n 
= 1, <1%; OR 9.63; 95% CI 1.40–412.09; P = 0.01). In addition, patients with S. aureus IE and 
left-sided valve IE were significantly older than those with S. aureus IE and right-sided valve 
IE (mean age right-sided valve IE: 38.2 years, mean age left-sided valve IE: 60.3 years; P < 
0.01). Prosthetic valve IE was not associated with in-hospital mortality (OR 1.43; 95% CI 0.54–
3.41; P = 0.40). There was a significant association between more than one IE manifestation 
on ECHO and in-hospital mortality (OR 2.69; 95% CI 1.12–6.10; P < 0.01). 
Men were more likely to have aortic valve vegetation than women (OR 1.77; 95% CI 1.16–
2.71; P = 0.01). Moreover, bicuspid aortic valves were marginally significantly more common 
in men than in women (OR 4.04; 95% CI 0.93–36.56; P = 0.05). There were no differences 
between men and women in terms of IV drug abuse (OR 0.92; 95% CI 0.60–1.41; P = 0.69), 
presence of prosthetic heart valves (OR 1.07; 95% CI 0.64–1.81; P = 0.79), in-hospital 
mortality (OR 0.84; 95% CI 0.38–1.93; P = 0.64), or surgical treatment for IE (OR 1.35; 95% 
CI 0.86–2.14; P = 0.17). 
  35 
5 DISCUSSION 
The burden of antibiotic resistance is known to be high in India (109). To combat this trend, 
the WHO recommends mapping and analysing antibiotic prescribing to identify areas in need 
of improvements (10). This thesis presents antibiotic prescribing practices in two private sector 
hospitals in the Ujjain district in Madhya Pradesh, India. When data were collected for the 
papers included here, access to diagnostic methods was limited and antibiotic prescribing 
guidelines were not implemented at either of the hospitals. Analysis of the antibiotic 
prescribing practices at the hospitals shows high and increasing use of antibiotics, even among 
patients with no apparent relevant indications for such treatment. Further, high and increasing 
use of broad-spectrum antibiotics as well as FDCs of antibiotics were seen at both hospitals. 
These findings indicate that there is a need for improvements in antibiotic prescribing practices 
and management of infectious diseases at these hospitals. This thesis also presents significant 
associations between bacterial aetiology and infectious manifestations detected by ECHO in 
patients with IE. ECHO is an important part of the routine management of IE in high-income 
settings as it is an effective method to identify it and conduct follow-ups. As it is a relatively 
easily implemented diagnostic method in resource-limited settings, the findings of this thesis 
could possibly be useful in the management of IE in such settings. 
5.1 AREAS OF POTENTIAL IMPROVEMENT IN ANTIBIOTIC PRESCRIBING 
PRACTICES IN A RESOURCE-LIMITED SETTING 
5.1.1 Antibiotics were sometimes prescribed without proper indication 
At medical ICUs at the two hospitals in Ujjain, most of the admitted patients were prescribed 
antibiotics (NTH 71% and TH 70%) (I). Despite the high antibiotic prescribing rates, only 12% 
of the patients at the medical ICUs at the NTH and 14% at the TH were registered with a 
diagnosis of infection. Even though infectious diseases were known to be common among 
those seeking health care in a previous study in Ujjain (110), most of the patients at the medical 
ICUs who were prescribed antibiotics had no diagnosis of infection registered (73% of the 
patients prescribed antibiotics at the NTH and 69% of the patients prescribed antibiotics at the 
TH had no diagnoses of infections or presumed symptoms of infection) (I). These findings are 
supported by a study conducted in an ICU of an Indian TH where 55% of the patients prescribed 
antibiotics had no reported bacterial infections (111). Antibiotics were also commonly 
prescribed as presumed symptomatic treatments at medical ICUs at both hospitals (at NTH, 
93% of the patients with presumed symptoms of infection recieved antibiotics and 85% at the 
TH) (I). In line with our results, high prescribing of antibiotics has been described in previous 
studies from medical ICUs and mixed ICUs in India, covering 80–95% of the patients (112-
114). 
Antibiotics were commonly prescribed among patients at the paediatric departments at the 
NTH (84% of patients). However, a lower percentage (44%) of patients at the paediatric 
departments at the TH were prescribed antibiotics (II). Paediatric patients with unspecified 
fever were more commonly prescribed antibiotics at the NTH (88% of the paediatric patients 
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with unspecified fever at the NTH and 47% at the TH), although antimicrobial agents are 
adviced not to be prescribed empirically to children with unspecified fever (115). In addition, 
the antibiotic prescribing rates among patients with acute gastroenteritis and viral fever, 
diagnoses for which antibiotics are not considered as proper treatment (54, 110, 116), were 
higher at the NTH compared with the TH; however, most of the patients with acute 
gastroenteritis and viral fever were prescribed antibiotics at the TH. An Indian study indicates 
that viral infections are the most common cause of fever in Indian children, and suggest that 
paediatric patients presenting with fever should be evaluated with clinical examination and 
relevant investigations but not treated with antibiotics (115). Antibiotics could possibly have 
been prescribed for superimposed bacterial infection among paediatric patients with viral fever 
at the NTH and TH. 
At both the NTH and the TH, samples were seldom sent for microbiological analysis, which 
suggests that most of the antibiotics were empirically prescribed on suspicion of infection 
(Papers I–III). However, at the NTH and the TH, laboratories for biochemical and 
microbiological confirmation of bacterial infections were easily available and free of charge, 
but despite that, underutilized at both hospitals. Underutilization of laboratory facilities has also 
been described in a study from a medicine department in a tertiary care, non-profit TH in 
Moradabad, India, where antibiotics accounted for 59% of all medicine prescriptions but only 
3% out of 180 patients underwent microbiological culture investigations (117). The reasons for 
underutilization of laboratory facilities need to be explored further. The lack of diagnostic 
investigations may have contributed to unnecessary prescribing of antibiotics or 
underprescribing of antibiotics in cases where an infection was present but not diagnosed. Since 
no diagnostic methods were routinely used either at the NTH nor at the TH, verification of the 
site of infections and infectious aetiologies were not possible to assess. Therefore, it was 
impossible to evaluate whether the antibiotics were also prescribed rationally or not. The access 
(antibiotics recommended as first-line treatments), watch (antibiotics recommended as second-
line treatments) and reserve (antibiotics recommended as third-line treatments) categorization 
of antibiotics provides a practical guide for proper antibiotic prescribing and can provide a basis 
for the development of local prescribing guidelines (107). In the TH, prescribing of watch, 
reserve and FDCs of antibiotics increased over 2008-2017 while at the NTH, prescribing of 
access, watch and FDCs of antibiotics increased among patients with severe infections (Paper 
III). Implementation of antibiotic prescribing guidelines might improve the prescribing of 
recommended antibiotics. Implementation of guidelines and diagnostic methods would enable 
more targeted prescribing to limit the unnecessary use of watch and reserve antibiotics. 
5.1.2 Adherence to antibiotic prescribing guidelines varied between 
hospitals 
The WHO has published international prescribing guidelines for antibiotic treatment 
(WHOLEM) and there are national lists of essential medicines in India including 
recommendations of antibiotics for both adult (NLEMI) and paediatric patients (IAP-LEM) 
(104, 106). Among antibiotic prescriptions for patients in medical ICUs, compliance with the 
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WHOLEM and NLEMI was higher at the TH compared with the NTH (prescriptions adherent 
to the WHOLEM, NTH 47% vs. TH 52%; P < 0.001; those to the NLEMI, NTH 53% vs. TH 
70%; P < 0.001, Paper I). Our results show lower adherence to guidelines compared with a 
study of a medical ICU in Gujarat, where 76% of the antibiotic prescriptions were adherent to 
the local antibiotic policy of the hospital (112). However, our results are more similar to another 
Indian study, also from Madhya Pradesh, that compared prescriptions from general 
practitioners in rural and urban areas, where 63% of the prescriptions in the urban area were 
adherent to lists of essential medicines compared with 75% of the prescriptions in the rural area 
(118) and to a study comparing prescriptions from general practitioners in rural and urban areas 
of Tamil Nadu showed that 35% of the prescriptions in the rural area and 40% in the urban area 
were adherent to the list of essential medicines (119). 
Among the paediatric patients, less than 40% of the antibiotic prescriptions were adherent to 
the IAP-LEM. However, the adherence to the IAP-LEM was significantly higher at the TH 
compared with the NTH (prescriptions adherent to the IAP-LEM: NTH 24% vs. TH 37%; P < 
0.001) (Paper II). At both hospitals, most paediatric patients with enteric fever were prescribed 
third-generation cephalosporins by the parenteral route although this is only recommended for 
patients with complicated or multi-drug-resistant enteric fever (120). Antibiotic treatment 
durations for paediatric patients with RTIs were a mean of 4.3 days at the NTH and 6.4 days at 
the TH. Antibiotic prescribing guidelines recommend 5–7 days of antibiotic treatment for 
children with mild or moderate forms of community-acquired pneumonia and up to 14 days 
for severe pneumonia, which suggests that the TH was more adherent to the guidelines (121). 
Overall, durations of hospital stay and antibiotic treatment durations were significantly longer 
at the TH (Papers I-III). The shorter durations of hospital stay at the NTH, could possibly be 
explained by economic factors. At the NTH, patients had to pay for their stay and treatment in 
hospital, which might have contributed to shorter durations of stay than in the TH, where 
patients did not pay and possibly could stay longer in hospital. Further, the physicians at the 
NTH were paid for the number of patients they admitted to the hospital, which might have 
contributed to shorter durations of hospital stay to be able to admit new patients. Two studies 
support our results, one from a medical ICU in a rural hospital in Gujarat, India–where patients 
had to pay for their treatment–showing a similar duration of hospital stay as the NTH (mean 
3.0 days) (112), and another study from an ICU in a TH in Northern India that reported a mean 
duration of hospital stay of 5.7 days for medical patients, which is more similar to the TH (113). 
According to guidelines, antibiotics should be prescribed by generic names rather than trade 
names, to ensure good quality antibiotics, give flexibility to dispense from available 
formulations and promote antibiotic access in LMICs (122, 123). Prescribing of generic name 
antibiotics was higher at the TH compared with the NTH (Papers I and II). High prescribing 
of trade names and low prescribing of generic name antibiotics have been described previously. 
A study from a tertiary care hospital in Uttar Pradesh showed that only 1.8% of the antibiotics 
were prescribed by generic name (117). The management of the TH controlled the purchase 
and supply of medicines at the hospital, possibly with the aim if obtaining good quality and 
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cost-effective medicines, and thus contributing to the higher prescription rate of generic name 
antibiotics. The high prescribing of trade name antibiotics at the NTH might be explained by 
the presence of medical representatives from pharmaceutical companies at the NTH (but not at 
the TH), which are known to put pressure on and influence the prescribers (28, 124-126). A 
study from the USA reported that prescribers exposed to representatives from pharmaceutical 
companies were more likely to prescribe medicines by trade name rather than generic name 
(125). 
There are few studies analysing why physicians do not follow recommendations for antibiotic 
treatment but one factor that is known to contribute to the prescribing of non-recommended 
antibiotic treatments is the limited availability of guidelines and lists of essential medicines, or 
limited knowledge about existing guidelines (126-128). When the data were being collected 
for this thesis, antibiotic prescribing guidelines were not implemented at either of the hospitals, 
which could explain the relatively low adherence to international and national guidelines. The 
higher compliance with the WHOLEM and the NLEMI or IAP-LEM at the TH could possibly 
be explained by the controlled purchase and supply of medicines, both for quality and economic 
reasons, because those included in lists of essential medicines are less expensive than, for 
example, the FDCs of antibiotics that were more commonly used at the NTH. Further, the 
feeling of responsibility among physicians participating in clinical education of medical 
students could have contributed to a more proper prescribing pattern at the TH. 
5.1.3 Prescribing of broad-spectrum antibiotics and FDCs of antibiotics was 
high and increasing 
Among patients in medical ICUs, -lactam antibiotics (J01C and J01D), especially 
combinations of penicillins including -lactamase antibiotics (J01CR) and third-generation 
cephalosporins (J01DD), quinolones (J01M), especially fluoroquinolones (J01MA) and 
imidazole derivatives (J01XD) were commonly prescribed at the TH. At the NTH, -lactam 
antibiotics (J01C and J01D), especially combinations of penicillins including -lactamase 
antibiotics (J01CR) and third-generation cephalosporins (J01DD) and FDCs of antibiotics were 
commonly prescribed among such patients (Paper I). Prescribing practices at the TH were 
similar to that in a medical ICU in a teaching hospital in South India, where third-generation 
cephalosporins (ceftriaxone), combinations of penicillins including -lactamase antibiotics 
(piperacillin with tazobactam) and imidazole derivatives (metronidazole) were the most 
commonly prescribed antibiotics during the study period (1 January 2014 to 31 December 
2014) (114). Further studies that support our results were from a rurally located community 
hospital in Chhattisgarh where penicillins, aminoglycosides, quinolones and imidazole 
derivatives were commonly prescribed (129) and a public sector tertiary care TH in a rural area 
in Chandigarh, where cephalosporins, aminoglycosides and metronidazole comprised 
approximately 70% of the antibiotics prescribed (130). At an ICU in a public sector TH in 
Nagpur, 32% of the in-patients were prescribed third-generation cephalosporins (111) and in 
an ICU in a NTH in Maharashtra where patients were charged for medical treatment, penicillins 
including -lactamase antibiotics and third-generation cephalosporins were commonly 
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prescribed, which supports the findings in our study (131). Lack of time, inadequate knowledge 
and the physicians’ perception of expectations from the patients, diagnostic uncertainty and 
fear of negative outcomes are factors that might contribute to prescribing broad-spectrum 
antibiotics (126-128). 
In the paediatric departments at the NTH, FDCs of antibiotics were most commonly prescribed 
among paediatric patients with acute gastroenteritis, RTIs and enteric fever while among 
paediatric patients with viral and unspecified fever, second- and third-generation 
cephalosporins were more commonly prescribed. At the TH, third generation cephalosporins 
were the most commonly prescribed antibiotics among all diagnosis groups of paediatric 
patients (Paper II). 
Prescribing FDCs of antibiotics among patients with severe infectious diseases increased both 
in the NTH and TH during 2008–2017 (Paper III). Prescribing FDCs of antibiotics is not 
recommended as they have been shown to drive antibiotic resistance, contributing to further 
unnecessary use (48). A factor that is known to contribute to prescribing FDCs of antibiotics is 
pressure from pharmaceutical companies (126-128). This factor is known to influence 
physicians’ prescribing practices in India (124). The higher rate of prescribing FDCs of 
antibiotics at the NTH could possibly be explained by the presence of representatives from 
pharmaceutical companies who commonly promote prescribing FDCs of antibiotics (132, 
133). The prohibition of representatives from pharmaceutical companies at the TH might have 
contributed to less such prescribing, as mainly generic medicines are procured by the TH’s 
management. 
5.2 IMPROVED MANAGEMENT OF INFECTIOUS DISEASES USING 
DIAGNOSTICS 
Diagnostics are essential to verify infections and their aetiology, to guide treatment regimens 
and to evaluate effects of interventions (134). Diagnostics are also important to contain the 
burden of infectious diseases in LMICs (135, 136). A panel of experts in global health has 
ranked modified molecular technologies for affordable, simple diagnostics of infectious 
diseases as the top-rated biotechnology for improving health in LMICs (134). Historically, 
diagnostic methods have been expensive and resource-demanding, making them not easily 
available in LMICs (134, 135). Although affordable diagnostics have the potential to reduce 
mortality in infectious diseases in LMICs, they have not been implemented (135, 136). So-
called point-of-care diagnostics are less dependent on contextual factors or explicitly trained 
staff and are specifically designed to be used in resource-limited settings (137). The recent 
development of affordable ultrasound machines of good quality has enabled the 
implementation of so-called point-of-care ultrasonography, which provides benefits for health-
care settings with limited access to advanced diagnostic methods (138). ECHO has also been 
evaluated to have high clinical utility in resource-limited settings (139). Thus, the cardiac 
manifestations of IE can be detected by ECHO with some basic training of health-care 
personnel (140). 
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At the KUH in Stockholm, both ECHO and microbiological analysis are parts of the routine 
management of patients with suspected or defined IE and there is a registry covering most of 
the patients with IE admitted to the hospital since 2008 (102). Paper IV aimed to assess any 
associations between IE manifestations detected by ECHO and bacterial aetiology in affected 
patients. The findings could possibly have importance in the management of such patients in a 
setting where ECHO is available but access to laboratory facilities for culture tests is limited 
or absent. 
5.2.1 How can IE be managed by ECHO – an example from a high-income 
setting 
In Paper IV, several associations between specific IE manifestations detected by ECHO and 
certain bacterial species were found; between native aortic valve vegetation and E. faecalis; 
between mitral valve vegetation and group B streptococci and viridans group streptococci; 
between tricuspid valve vegetation and S. aureus among patients with IV drug abuse; between 
perivalvular abscesses and CoNS; and between CIED-associated IE and HACEK (combination 
of Haemophilus species, Aggregatibacter species, Cardiobacterium hominis, Eikenella 
corrodens and Kingella Kingae) and CoNS. Consistent with our results, it has been shown that 
CoNS caused perivalvular extension of infections in patients with IE (89). The association 
between tricuspid valve IE and S. aureus infection has been reported in a previous study (88). 
The most common IE manifestations were vegetations in the mitral (40%), aortic (39%) and 
tricuspid valves (22%), reminiscent of a study of 68 autopsies of patients with IE reporting that 
35% of patients had mitral valve vegetation, 26% had aortic valve vegetation and 5% had 
tricuspid valve vegetation (141). The high prevalence of tricuspid valve vegetation in our study 
might be explained by the high percentage of patients with a history of IV drug abuse (32%). 
Further supporting our findings, a multicentre study of 1,055 patients with IE in Europe and 
the USA showed that mitral valve followed the aortic valve vegetations were the most common 
ECHO manifestations (142). TTE is a good method for visualization of native valve IE, with 
96% sensitivity, which is equal to the sensitivity of TEE for native valve IE (64, 143, 144). 
However, in patients with prosthetic heart valves, IE manifestations are more difficult to detect 
with TTE because of shading from the prosthesis or chordae tendinae, and the relatively low 
resolution of TTE giving a sensitivity of 70% compared with 92% for TEE. Therefore, TEE is 
highly recommended for patients with prosthetic heart valves (64, 144, 145). Further, ECHO 
findings might not differ between patients with IE undergoing ECHO early (<2 days) or late 
(2 days) after the initiation of antibiotic treatment (90). 
The most common bacterial species were S. aureus (49%) and viridans group streptococci 
(21%). Previous studies of patients with IE in industrialized countries also showed that S. 
aureus is the most common bacterium causing IE (90, 146-148) and that the prevalence rates 
of viridans group streptococci are high and increasing (145, 149). S. aureus has been described 
as being linked to higher mortality rates among patients with IE, compared with other bacterial 
species (90, 146-148). In our study, S. aureus was not associated with higher in-hospital 
mortality; however, 51% of all patients with S. aureus aetiology had a history of IV drug abuse. 
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Such patients are known to be commonly affected with S. aureus and to acquire right-sided 
rather than left-sided valve vegetations (150-152). Among the patients with S. aureus-related 
IE, patients with right-sided valve vegetations were younger and had lower in-hospital 
mortality compared with the patients with left-sided valve vegetations. The overall in-hospital 
mortality in our study (7%) was lower than the previously reported rates of 15–20% (153, 154), 
but similar to a Swedish study showing a 30-day crude mortality rate of 10.4% (146). The 
relatively low age of the included patients with IE (mean 57.1 years) and high prevalence of 
right-sided IV drug abuse-associated IE might have contributed to the low in-hospital mortality 
in our study. Perivalvular abscess was associated with in-hospital mortality, a finding supported 
by Lauridsen et al. who reported that perivalvular abscess predicted 1-year mortality in patients 
with left-sided native valve S. aureus-linked IE (155). 
Patients with IE with a history of IV drug abuse were less commonly treated with cardiac 
surgery compared with those with no such history, which might explain the relatively low rate 
of patients who underwent surgical treatment in our study (28%). Surgical treatment was more 
common among patients with aortic valve vegetation, CIED-associated endocarditis or a 
perivalvular abscess. In our study, there was an association between prosthetic valve IE and an 
aetiology of E. faecalis and a negative association between prosthetic valve IE and S. aureus. 
These findings differ from previous studies showing that S. aureus and CoNS were common 
among patients with prosthetic valve IE (149). In our cohort, there were more male than female 
patients included (ratio approximately 2:1), a finding that is supported by earlier studies of 
patients with IE (156, 157). Male patients with IE were more likely to have aortic valve 
vegetations than female, which is partly consistent with previous studies (157, 158). In-hospital 
mortality and surgical treatment were equal among male and female patients, although there 
are previous studies reporting higher mortality rates as well as a lower rate of surgical treatment 
among female patients (88). 
5.2.2 Can ECHO be implemented for improved management of IE in 
resource-limited settings? 
The results from Paper IV suggest the possibility of predicting bacterial aetiology with ECHO, 
as certain IE manifestations detected by ECHO are associated with specific bacterial aetiology 
in patients with IE. This might have importance in a setting where culture tests are scarce or 
absent, but ECHO might be possible to implement. According to the modified Duke criteria, 
the diagnosis of definite IE can be stated not only with the two major criteria fulfilled (blood 
culture and imaging both positive for IE) but also if one major and three minor criteria, or five 
minor criteria are present (Table 1) (64, 67). Consequently, the diagnosis of definite IE could 
be established using ECHO and clinical evaluation of the patients, also if microbiological 
culture investigations are absent or limited, which could be valuable in resource-limited health-
care facilities. 
Significant associations were found between ECHO-detected IE manifestations and specific 
bacterial species among Swedish patients with IE, suggesting that the prediction of bacterial 
aetiology with ECHO might be possible in some cases. To ensure the findings can be applicable 
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to populations other than this cohort from Stockholm, it will be important to compare clinical 
characteristics between the patients included in our cohort, and patients in other populations. 
The management and causes of IE, as well as patient characteristics, might also differ between 
high-income countries and LMICs. Comparing the cohort of patients with IE from Stockholm 
with previously described characteristics of patients with IE in India shows that there are both 
differences and similarities. Table 12 shows a summary of the findings from four Indian studies 
as well as from Paper IV. 
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Table 12. Clinical characteristics of patients with IE in four studies from tertiary care 
hospitals in India, and comparisons with Paper IV 
 Choudhury et al.a 
Chandigarh, 
Punjab 
Subbaraju et al.b 
Manipal, 
Karnataka 
Soman et al.c 
Mumbai, 
Maharashtra 
RM et al.d, 
Chennai, Tamil 
Nadu 
Paper IV, 
Stockholm, 
Sweden 
Study period 1981–1991 2007–2013 2007–2015 2010–2015 2008–2017 
Number of patients, n 186 139 53 120 492 
Definite IE/possible IE, n 
(%); n (%) 
186 (100); 0 (0) 95 (68); 44 (32) 44 (83); 9 (17) 120 (100); 0 (0) 492 (100); 0 (0) 
Age, mean years 25  48 >77% older than 
40 years 
53 57 
Sex ratio, male: female - 2.2:1 - 2.5:1 2:1 
Prosthetic valves, n (%) 2 (1) 5 (4) 15 (28) 17 (14) 92 (19) 
RHD, n (%) 78 (42) 43 (31) 7 (13) 18 (15) 2 (0) 
Underlying heart disease, n 
(%) 
GUCH: 33 (17) 135 (97) 29 (55) 90 (62) 322 (65) 
IV drug abuse, n (%) 1 (<1) 0 (0) - 0 (0) 156 (32) 
Staphylococci, n (%) 37 (20) MSSA: 15 (11), 
CoNS: 3 (2) 
4 (8) 11 (9) SA: 239 (49), 
CoNS: 24 (5) 
Streptococci, n (%) 34 (18) VGS: 43 (31) VGS: 14 (26) 19 (16) 
VGS: 16 (13) 
133 (27) 
VGS: 102 (21) 
Enterococci, n (%) - 18 (13) 9 (17) 16 (13) 52 (11) 
Positive ECHO, n (%)  121 (64) 131 (94) 53 (100) 86 (97) 492 (100) 
ECHO findings, n (%) - MV: 80 (58), 
AV:27 (19), TV:8 
(6), PV: 3 (2) 
- MV: 50 (42), 
AV:47 (39), TV:7 
(6), >1 valve: 16 
(13) 
MV:195 (40), 
AV:190 (39), 
TV:108 (22), >1 
valve: 83 (17) 
Surgical treatment, n (%) - 5 (4) 26 (49) 31 (26) 139 (28) 
In-hospital mortality, n (%) 47 (25) 24 (17) 11 (21) 12 (10) 33 (7) 
Adapted from: a(159)b(74)c(71)d(70). AV, aortic valve; CoNS, coagulase-negative staphylococci; ECHO, echocardiography; GUCH, grown-
up congenital heart disease; IE, infective endocarditis; IV, intravenous; MSSA, methicillin-sensitive Staphylococcus aureus; MV, mitral 
valve; PV, pulmonary valve; RHD, rheumatic heart disease; SA, Staphylococcus aureus; TV, tricuspid valve; VGS, viridans group 
streptococci. 
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A study from 1992 conducted in Chandigarh, Punjab, of 186 patients admitted between 1981 
and 1991 with definite IE, showed that RHD was present in 42% of the patients (159). There 
seems to be a variation in presence of RHD in patients with IE in India according to three 
relatively recent studies from tertiary care centres in three Indian cities. Two studies published 
in 2018, one conducted in Mumbai, including 53 patients for 2007–2015 and one from 
Chennai, including 145 patients admitted during 2010–2015, showed presence of RHD in 13% 
and 15% of the patients, respectively (70, 71). A study from Manipal (2007–2013) of 139 
patients with IE reported a higher incidence of RHD (31%). Thus, RHD seems to be more 
common among Indian patients with IE compared with our cohort with only two such patients 
(<1%, Paper IV). In the two more recent Indian studies, the rates of underlying heart diseases 
were similar to our study (Table 12). The three studies from Mumbai, Chennai and Manipal 
showed that viridans group streptococci were the most common bacterial strains with similar 
rates to our Paper IV (70, 71, 74). The three studies showed a much lower rate of S. aureus-
associated IE compared with Paper IV, which might be explained by the absence of IV drug-
abuse patients in their study populations (<1%) compared with 32% of patients with history of 
IV drug abuse in our cohort (70). The presence of enterococci seemed to be relatively similar 
between the Indian studies and those we report in Paper IV (Table 12). In the study from 
Chennai, the rates of mitral and aortic valve vegetations were similar to our study (Chennai, 
42% and 39%, vs Paper IV, 40% and 39%), but tricuspid valve vegetation seemed to be more 
common in the results of Paper IV, also possibly associated with the higher rate of IV drug 
abuse (70). The higher rate of history of drug abuse probably contributed to the higher rate of 
tricuspid valve vegetations in Paper IV. Tricuspid valve vegetations in Indian patients were 
mostly present in patients with CIEDs, immunocompromised patients with central venous 
catheters, and among patients with congenital heart diseases (160). The rate of surgical 
treatment was similar in the studies from Mumbai and Chennai, as in Paper IV, but it should 
be noted that the Indian studies were from hospitals with access to cardiac surgery, which is 
not always the case, so surgery rates may vary. For example, in the study from Manipal, only 
4% of patients were surgically treated. 
Consequently, ECHO is important for the diagnosis, cardiac evaluation and follow-up of IE. 
The results from Paper IV suggest that ECHO might also have a role in the prediction of a 
bacterial aetiology for IE, which can be valuable in resource-limited health-care facilities. 
Ultrasonography has been shown to be possible to implement in health-care facilities with 
limited resources, because it requires fewer economic and personnel assets than many of the 
conventional diagnostic methods (80, 84, 140, 161). However, the effects of implementation 
of ECHO in the management of infectious diseases, such as IE, need to be further evaluated in 
resource-limited health-care facilities. 
5.2.3 Implications for the treatment of IE 
Successful treatment of IE relies on effective antibiotic treatment (64). The treatment 
guidelines for IE published by the European Society of Cardiology and the American Heart 
Association are mostly based on bacterial aetiology (64, 66). In resource-limited settings, the 
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bacterial aetiology can remain unknown if access to microbiological analysis is limited or 
absent. The results of this thesis show that ECHO might have a role in the prediction of bacterial 
aetiology of IE, but it might not be sufficiently robust to guide bacteria-specific treatment alone. 
In health-care settings with access to microbiological analysis, the so-called blood culture-
negative IE is a phenomenon where no causative microorganism can be verified by the usual 
blood culture methods. Most studies report that 5–10% of IE cases are blood culture-negative 
(66) but this can occur in up to 31% of all cases, which might cause substantial predicaments 
both for making a correct diagnosis and for treatment (64). Empirical treatments that cover the 
most common bacterial aetiologies of IE are often required. According to the guidelines, blood 
culture-negative IE should be treated in consultation with a specialist in infectious diseases, 
with the focus being to identify a pathogen and to make the most appropriate choice of 
antibiotic treatment (64, 66). An evaluation of patient-specific factors in relation to 
epidemiological factors is recommended. The epidemiological factors that should be taken into 
consideration are: any history of prior infections; risk factors or predisposing factors for IE; 
prior exposure to antibiotics; extracardiac sites of infection; and the clinical course and severity 
of the current infection (66). Evaluation of clinical and additional laboratory data often enables 
revision of empirical treatments to a more targeted treatment regimen (66). In addition to its 
diagnostic value, ECHO can be used for evaluation of the severity of valve infection and 
cardiac complications, in decision-making regarding the need for surgery, in the evaluation of 
treatment, and in follow-up (64, 66). 
According to our findings in Paper IV, ECHO could have a role in clinical evaluation to guide 
the management and treatment of IE, providing knowledge regarding how certain bacteria 
manifest in this disorder. To highlight their locations and manifestations, associations with risk 
factors or predisposing factors for IE, and their associations with certain outcomes, the pattern 
of different bacteria might be of clinical value for management and treatment. This could be 
useful also in resource-limited settings, where ECHO could possibly contribute to better 
management of patients with IE. According to the results from Paper III, only 9 patients out 
of 243,774 admitted to the NTH and TH between 2008 and 2017, were registered with IE, 
suggesting underdiagnosing of IE at the two hospitals in Ujjain. Implementing ECHO in such 
settings could contribute to the diagnose, management, treatment and follow-up in patients with 
IE.  
5.3 METHODOLOGICAL CONSIDERATIONS 
5.3.1 Strengths 
A strength of Papers I-III was the prospective and consecutive mode of data collection. The 
same method for data collection was used at both hospitals, which enabled good comparability 
of data. At both hospitals, nurses were trained continuously in data collection to ensure its 
quality and to involve new staff in the collection of data quickly. Another strength was the 
computerization of records with a possibility to extract data to follow prescribing patterns. 
Antibiotic prescribing was measured using the internationally accepted ATC/DDD 
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methodology. Measuring antibiotic prescribing with DDDs enables comparisons between 
different health-care facilities and comparisons of prescribing over time. In combination with 
data on diagnoses or indications for prescribing, this methodology can also be used to assess 
the rationality of prescribing. It should be noted that the DDD methodology is based on 
medicine use in adult patients, and not in paediatric patients. However, DDDs can also be used 
to compare antibiotic prescribing for children, between different health-care facilities, and for 
prescribing over time. 
In Paper IV, a strength was the information on comorbidities and underlying heart diseases 
provided by the SRIE. Comorbidities and underlying heart diseases, such as degenerative 
structural heart disease, or any history of IV drug abuse and RHD, can contribute considerably 
to aspects of bacterial aetiology, manifestations and mortality in patients with IE. The SRIE 
includes information about several comorbidities and underlying heart diseases such as RHD, 
history of IV drug abuse and congenital heart disease, which enables comparisons of the results 
from studies in other populations of patients with IE.  
5.3.2 Limitations 
Although the data for Papers I-III were collected in a controlled manner, there was a risk of 
missing data, because data collection and entry were both manual. The registered diagnoses 
were not confirmed by culture results, unless ordered by the consultant in charge or in any other 
way. Consequently, most of the diagnoses were based on clinical suspicions and some patients 
might have been incorrectly diagnosed. Absence of culture results makes it difficult to assess 
whether the antibiotics were prescribed rationally. However, by analysing compliance with 
existing guidelines on empirical prescribing for certain infectious diagnoses as well as 
analysing compliance with the WHO’s antibiotic categories of access, watch and reserve, the 
appropriateness of antibiotic prescribing practices in the NTH and TH could be discussed. 
Another limitation was the absence of medical records and documentation of previous medical 
history for the patients included in Papers I-III. Because there were no medical records or 
documentation available, no predisposing factors among the patients could be evaluated. 
For Paper IV, the SRIE included the locations of IE manifestations and information about 
known valvular disease prior to a diagnosis, but no detailed information about the size or 
number of vegetations, details about valve function, or type or severity of degenerative 
structural heart diseases was available. This would have been interesting to present together 
with the results, as these factors can contribute to important aspects of bacterial aetiology, 
manifestations and mortality. Information about the time for primary prosthetic valve 
implantation was not available in the SRIE, which made it impossible to present or distinguish 
between early- and late-onset prosthesis-related IE. Further, no blood test results or follow-up 
information such as 1-year mortality was included in the SRIE. Unfortunately, it was not 
possible to analyse more unusual aetiologies of IE, such as gram-negative bacteria and fungi, 
because there were very few cases with these pathogens in our study. Future studies with larger 
study populations and prospective designs would be of interest to explore the possible 
associations between manifestations detected by ECHO, and bacterial aetiology in IE. It should 
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be noted that Paper IV reflects a population of patients with IE, admitted to a university TH in 
Stockholm, Sweden, so the results might differ from other populations of patients with IE.  In 
this thesis, possible benefits of implementing ECHO in resource-limited settings have been 
discussed. However, the equipment used at the KUH might not be comparable to the equipment 
that would possibly be used in resource-limited settings. The equipment used in such settings 
could be less advanced, and the ability to identify IE manifestations with such equipment would 
need to be evaluated before implementation.   
The SRIE includes information on antibiotic prescribing, which generally followed the 
Swedish national guidelines for antibiotic treatment of IE. I considered including the antibiotic 
prescribing among the patients with IE in Paper IV, but chose not to, as the purpose of the 
paper was to include the diagnostics aspect rather than the antibiotics aspect. 
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6 CONCLUSIONS 
The main conclusions from this thesis are as follows. 
 Antibiotics were commonly prescribed at the two study hospitals to patients with no 
evident indication for such treatments, indicating less rational use of antibiotics. 
 Adherence to recommendations regarding antibiotic treatment for given indications 
varied between the hospitals, suggesting there is a need for improved knowledge about 
guidelines and lists of essential medicines among the prescribers. 
 Prescribing FDCs of antibiotics was higher at the NTH than at the TH. Prescribing 
FDCs of antibiotics increased over 2008–2017 at both hospitals. 
 Extensive prescribing of broad-spectrum antibiotics was seen at both hospitals, 
although diagnostic methods were rarely used to confirm or exclude infections or their 
bacterial aetiologies. 
 ECHO as part of the standard management of IE in high-income settings contributes to 
verification of the diagnosis, evaluation and follow-up. 
 ECHO can be used to identify cardiac manifestations of IE but might also give a 
suggestion of bacterial aetiology as some IE manifestations detected by ECHO have 
been shown to be associated with certain bacterial species.  
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7 REFLECTIONS FOR THE FUTURE 
7.1 RESEARCH 
This thesis presents different ways of analysing data regarding antibiotic prescribing practices 
in a resource-limited setting. It further presents an evaluation of ECHO as a diagnostic method 
for IE in a high-income setting, suggesting that assessment of cardiac manifestations by ECHO 
can help evaluate the severity of the disease and might also indicate the bacterial aetiology in 
patients with IE. These methods of analysing data can be reused for future investigations. The 
findings from the studies in this thesis suggest some future research questions as follows. 
 Why are antibiotics prescribed to patients with no apparently proper indication for 
antibiotic treatment? 
 How can antibiotic prescribing guidelines or essential lists of medicines be 
implemented in resource-limited settings to improve prescribing patterns? 
 Why are diagnostic methods not used among prescribers with access to such methods 
in resource-limited settings? 
 Do interventions that target physicians’ knowledge, attitude and practice towards 
antibiotic prescribing and the management of infectious diseases affect their practice? 
 Would implementation of diagnostic methods improve the management of infectious 
diseases and rationalize the antibiotic prescribing practices in resource-limited 
settings? 
 Would implementation of ECHO in a resource-limited setting improve the 
management of IE? 
 Would it be possible to find associations between bacterial species and IE 
manifestations detected by ECHO in samples of patients with IE from populations in 
other settings, for instance in resource-limited settings? If so, do the associations differ 
between different settings? 
7.2 POLICY AND PRACTICE 
There is a global need for the improved use of antibiotics and management of infectious 
diseases (9, 10, 12, 162, 163). Interventions should be designed to ensure the long-term 
successful prevention and treatment of infectious diseases, with the intention of keeping 
antibiotics as an available, effective and safe treatment with quality-assured medicines (10). 
These interventions should be implemented at all levels of health care as well as in the general 
public (8). Interventions need to be adapted to the setting in which they are aimed to be 
implemented, to increase their impact (19). Interventions improving the use of antibiotics and 
management of infectious diseases in resource-limited settings – such as the implementation 
of an antibiotic stewardship programme and enforcement of an antibiotic restriction policy at 
ICUs–have shown promising results (112, 164). The results presented in this thesis suggest 
further interventions to improve antibiotic prescribing practices and management of infectious 
diseases in hospitals in the Ujjain district as well as in other hospitals in similar resource-limited 
settings. Obstacles and contributing factors, suggested improvements and goals for 
rationalizing the antibiotic prescribing and improve the management of infectious diseases in 
the NTH and the TH as well as similar resource-limited settings, are presented in Figure 5. 
 
 50 
Further, lack of diagnostics complicates the management of patients with suspected infectious 
diseases, both in terms of determining the site of infection and the infectious etiology. The 
results from this thesis show that ECHO is a method that can be used to diagnose IE, to provide 
additional information about possible cardiac comorbidity, and to evaluate the severity of the 
disease. This is valuable information that can guide the management of the patients with IE. 
By implementing ECHO in a resource-limited setting, the management of the patients with IE 
could possibly be improved.
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Figure 5. Present situation, suggested improvements and goals for improvement of antibiotic prescribing to contain antibiotic resistance in 
resource-limited settings. 
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APPENDIX I. ANTIBIOTICS GROUPED BY THEIR 
ANATOMICAL THERAPEUTIC CHEMICAL 
CLASSIFICATION CODE AND CATEGORIZED AS 
ACCESS, WATCH, RESERVE ANTIBIOTICS OR FIXED-
DOSE COMBINATIONS OF ANTIBIOTICS (PAPER III) 
ATC code Antibiotic group Specific antibiotics Antibiotic 
category 
J01A Tetracyclines Doxycycline  Access 
Tigecycline Reserve 
J01B Amphenicols Chloramphenicol Access 
J01 group 1: J01CA,  
J01CE,  
J01CF,  
J01CG 
Penicillins with extended 
spectrum, -lactamase 
sensitive penicillins, -
lactamase resistant penicillins, 
-lactamase inhibitors 
Amoxicillin, ampicillin, benzathine benzylpenicillin, 
benzylpenicillin, cloxacillin, phenoxymethylpenicillin, 
procaine benzylpenicillin, piperacillin, tazobactam 
Access 
J01CR Combinations of penicillins 
including -lactamase 
inhibitors 
Amoxicillin with clavulanic acid Access 
Piperacillin with tazobactam Watch 
J01D -lactam antibiotics Cefalexin, cefazolin, cefadroxile, cefradine, cefuroxime Access 
Cefixime, ceftriaxone, cefotaxime, cefoperazone, 
cefodoxime, ceftazidime, meropenem, imipenem, 
cilastin, faropenem 
Watch 
Aztreonam, cefepime, ceftaroline Reserve 
J01E Sulphonamides and 
trimethoprim 
Sulfamethoxazole with trimethoprim  Access 
J01F Macrolides Clindamycin Access 
Azithromycin, clarithromycin, erythromycin, 
lincomycin, roxithromycin 
Watch 
J01G Aminoglycosides Gentamicin, netilmicin, kanamycin, tobramycin, 
streptomycin, amikacin 
Access 
J01M Quinolones and 
fluoroquinolones 
Ciprofloxacin, levofloxacin, moxifloxacin, norfloxacin, 
orfloxacin, gemifloxacin, pazufloxacin, gatifloxacin, 
prulifloxacin 
Watch 
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ATC code Antibiotic group Specific antibiotics Antibiotic 
category 
J01R 
 
 
 
Combinations of antibiotics 
 
 
 
 
 
 
 
Ampicillin with cloxacillin; amoxicillin with 
cloxacillin; azithromycin with ambroxol; cefixime with 
ornidazole; cefoperazone with sulbactam; ceftriaxone 
with sulbactam; ceftriaxone with tazobactam; 
norfloxacin with tinidazole; ofloxacin with ornidazole; 
ofloxacin with tinidazole; cefixime with clavulanate 
potassium; cefixime with clavulanic acid; cefixime with 
cloxacilline; cefixime with ofloxacin; cefixime with 
tazobactam; cefotaxime with sulbactam; cefpodoxime 
with clavulanic acid; cefpodoxime with cloxacillin; 
cefpodoxime with dicloxacillin; meropenem with 
sulbactam; ceftazidime with tazobactam; cefuroxime 
with clavulanic acid; ciprofloxacin with ornidazole; 
ciprofloxacin with tinidazole; efoperazone with 
sulbactam; levofloxacin with ornidazole; cefixime with 
azithromycin; cefpodoxime with potassium clavulanate; 
ceftriaxone with clavulanic acid 
FDCs of antibiotics 
J01X Other antibiotics Metronidazole (J01XD01), nitrofurantoin, tinidazole, 
ornidazole, spectinomycin 
Access (P01AB01 
Metronidazole 
included) 
Teicoplanin, vancomycin Watch 
Polymyxin B, colistin, fosfomycin, linezolid, 
daptomycin 
Reserve 
For antibiotic classification, the 2019 ATC classification was used. ATC, Anatomical Therapeutic Chemical; FDC, fixed-
dose combination. 
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APPENDIX II. ANTIBIOTICS PRESCRIBED FOR PATIENTS WITH SEVERE INFECTIONS AT 
THE NTH AND TH IN 2008–2017 (PAPER III)  
 Antibiotic prescribing in DDDs per 1000 patient days    
Cellulitis at the NTH 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 % Slope, ta P valueb 
J01CR 4.12 4.44 0.73 4.78 3.17 4.90 5.77 4.33 3.24 7.11 16 2.32 0.02 
J01D 13.11 9.01 1.98 11.52 5.09 4.28 12.50 7.54 14.18 3.06 32 6.33 <0.01 
J01R 6.53 5.60 3.12 2.60 4.70 3.46 3.01 6.78 6.12 1.84 17 6.97 <0.01 
J01X 9.25 15.76 3.68 3.34 1.30 1.05 1.62 1.08 1.42 1.48 15 3.31 <0.01 
Cellulitis at the TH 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 % Slope, ta P valueb 
J01CR 10.84 7.45 4.24 7.14 9.47 8.99 10.07 8.03 16.29 13.33 19 4.91 <0.01 
J01D 4.48 6.01 9.32 6.22 4.76 4.66 6.87 6.53 9.98 2.10 12 5.58 <0.01 
J01G 9.33 13.53 9.11 9.26 14.55 10.47 10.01 6.37 15.64 5.45 21 0.44 0.66 
J01M 10.20 8.70 3.35 5.66 9.00 4.51 4.30 3.31 9.11 6.22 13 2.66 <0.01 
J01X 6.53 3.70 7.38 6.50 6.86 10.22 7.89 3.84 9.17 3.91 13 2.27 0.02 
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Peritonitis at the NTH 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 % Slope, ta P valueb 
J01CR 3.71 4.26 3.85 10.23 3.06 5.70 4.45 5.89 5.67 4.40 16 4.98 <0.01 
J01D 26.28 6.43 4.54 4.34 10.36 7.35 1.41 7.78 8.04 5.06 25 1.34 0.18 
J01R 8.58 6.14 5.29 5.55 5.01 1.14 3.09 5.02 6.19 1.40 15 8.67 <0.01 
J01X 16.03 11.72 11.64 9.09 4.57 2.49 1.58 1.81 3.54 1.97 20 10.95 <0.01 
Peritonitis at the TH 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 % Slope, ta P valueb 
J01CR 5.84 4.39 6.68 5.55 10.92 9.13 16.54 13.44 13.36 5.35 15 10.16 <0.01 
J01D 4.00 4.95 9.63 9.44 6.87 2.76 6.04 7.64 15.87 7.73 12 17.55 <0.01 
J01G 10.08 4.65 11.08 9.94 11.84 6.49 11.43 11.87 8.64 4.08 15 8.13 <0.01 
J01M 16.05 10.72 3.27 6.40 11.99 5.83 11.60 12.86 15.42 3.56 16 2.92 <0.01 
J01X 15.75 9.55 16.85 17.73 15.44 13.92 22.64 17.30 23.05 5.24 26 8.69 <0.01 
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Pneumonia at the NTH 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 % Slope, ta P valueb 
J01CR 11.54 5.01 4.05 4.27 4.95 4.61 5.96 5.79 8.79 8.17 29 -0.91 0.36 
J01D 7.75 6.92 4.22 8.53 3.24 2.95 1.37 4.44 4.23 4.18 22 -1.38 0.17 
J01M 1.00 0.49 0.47 0.50 2.41 0.83 3.98 7.34 3.47 1.18 10 2.54 0.01 
J01R 5.74 4.61 3.51 2.55 4.21 4.76 5.27 4.61 3.72 4.82 20 5.65 <0.01 
Pneumonia at the TH 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 % Slope, ta P valueb 
J01A 16.44 11.85 14.23 8.45 13.76 10.18 7.21 2.91 2.25 18.79 25 1.81 0.07 
J01CR 8.45 12.64 10.66 1.91 8.26 15.71 20.02 19.21 15.38 13.27 30 6.65 <0.01 
J01D 3.85 6.01 5.04 10.91 7.24 4.65 3.94 3.81 15.31 20.74 19 12.87 <0.01 
J01M 15.87 9.36 8.72 5.72 3.88 2.04 1.61 1.77 4.65 7.44 14 1.89 0.06 
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Sepsis at the NTH 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 % Slope, ta P valueb 
J01CR 5.05 3.90 2.13 1.97 2.23 2.55 3.01 6.90 3.47 6.66 21 1.10 0.27 
J01D 10.74 7.47 1.19 3.27 4.63 3.86 4.77 6.37 4.29 1.70 27 -4.67 <0.01 
J01R 7.55 3.66 1.71 1.33 2.09 3.36 1.84 3.07 2.63 2.76 17 3.17 <0.01 
J01X 12.22 6.54 4.51 0.99 0.79 0.00 1.28 1.02 0.72 0.00 16 -6.07 <0.01 
Sepsis at the TH 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 % Slope, ta P valueb 
J01A 14.61 7.67 9.59 1.83 4.31 2.95 4.26 0.00 0.00 3.13 11 -5.50 <0.01 
J01CR 1.84 11.18 27.87 2.76 5.09 1.83 8.04 7.09 7.79 7.09 19 -5.07 <0.01 
J01D 1.37 5.48 8.48 3.03 5.87 3.79 12.27 5.57 7.21 4.89 13 -5.20 <0.01 
J01M 11.51 1.75 14.45 11.32 3.13 0.11 4.75 0.91 2.81 3.62 13 -8.49 <0.01 
J01X 8.95 12.93 15.34 7.08 9.18 6.36 12.60 0.91 6.00 4.07 19 -15.48 <0.01 
The antibiotics presented comprised >75% of the total amount of antibiotic prescribing within each diagnosis group. Numbers are presented as total incidences of antibiotic prescribing of antibiotic groups for 
each year, in DDD/1000 patient days and as percentage of the total prescriptions of antibiotics for each diagnosis and hospital during the study period. a t values were obtained by linear regression; a positive t 
indicates a positive trend and a negative t indicates a negative trend of prescribing. bP values were obtained from linear regression, evaluating the differences in antibiotic prescribing over the 10-year period. 
Statistically significant P values indicate a significant trend and are marked in bold font. DDD, defined daily doses; NTH, non-teaching hospital; TH, teaching hospital.
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APPENDIX III. DISTRIBUTION OF IE MANIFESTATIONS AND BACTERIAL SPECIES 
COMPRISING 90% OF THE AETIOLOGIES AMONG PATIENTS WITH IE (PAPER IV) 
Values are presented as n,number of patients; (% of patients); odds ratio; 95% confidence interval; P values. Statistically significant associations (P < 0.05) are shown in bold. CIED, cardiovascular implantable electronic device; CoNS, 
coagulase-negative staphylococci; HACEK, combination of Haemophilus species, Aggregatibacter species, Cardiobacterium hominis, Eikenella corrodens, and Kingella kingae; IE, infective endocarditis; KUH, Karolinska University 
Hospital. 
 
Aortic valve vegetation Mitral valve vegetation Tricuspid valve vegetation Pulmonary valve vegetation CIED-associated IE Perivalvular abscess 
Total, n 
(%) 
All patients, n (%) 190 (39) 195 (40) 108 (22) 9 (2) 24 (5) 29 (6) 
 
Staphylococcus 
aureus 68 (14), 0.43, 0.29-0.63; <0.01 84 (17), 0.69, 0.47-1.01; 0.05 88 (18), 6.79, 3.93-12.11; <0.01 8 (2), 8.73, 1.15-388.69; 0.01 11 (2), 0.89, 0.35-2.20; 0.78 11 (2), 0.63, 0.26-1.44; 0.24 239 (49) 
CoNS 16 (3), 3.38,1.33-9.29; <0.01 6 (1), 0.49, 0.16-1.33; 0.13 2 (0), 0.31, 0.03-1.30; 0.13 0 (0) 4 (1), 4.48, 1.01-15.15; 0.02 5 (1), 4.87, 1.30-15.01; <0.01 24 (5) 
Viridans group 
streptococci 45 (9), 1.33, 0.84-2.12; 0.20 51 (10), 1.70, 1.07-2.71; 0.02 5 (1), 0.14, 0.04-0.36; <0.01 0 (0) 1 (0), 0.16, 0.04-1.00; 0.04 6 (1), 1.00, 0.32-2.61; 1.00 102 (21) 
Group B streptococci 4 (1), 0.91, 0.19-3.62; 1.00 9 (2), 7.13, 1.44-68.33;<0.01 0 (0) 0 (0) 0 (0) 1 (0), 1.62, 0.04-12.11; 0.49 11 (2) 
Group D 
streptococci 3 (1), 1.20, 0.17-7.15; 1.00 4 (1), 2.05, 0.34-14.14; 0.44 0 (0) 0 (0) 0 (0) 1 (0), 2.70, 0.06-23.37; 0.35 7 (1) 
Group G 
streptococci 4 (1), 1.60, 0.29-8.70; 0.49 3 (1), 0.91, 0.14-4.73; 1.00 1 (0), 0.50, 0.01-3.99; 1.00 0 (0) 0 (0) 0 (0) 8 (2) 
Enterococcus faecalis 30 (6), 2.64, 1.40-5.08; <0.01 19 (4), 0.93, 0.48-1.75; 0.80 7 (1), 0.55, 0.20-1.28; 0.15 0 (0) 2 (0), 0.80, 0.09-3.41; 1.00 2 (0), 0.64, 0.07-2.69; 0.76 50 (10) 
HACEK 6 (1), 1.06, 0.31-3.40; 0.91 3 (1), 0.37, 0.07-1.40; 0.18 2 (0), 0.54, 0.06-2.44; 0.54 1 (0), 4.19, 0.09-34.97; 0.25 4 (1), 8.31, 1.76-31.08;<0.01 1 (0), 1.15, 0.03-8.07; 0.60 15 (3) 
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Values are presented as n, number of patients; (% of patients); odds ratio; 95% confidence interval; P values. Statistically significant associations (P < 0.05) are shown in bold. CoNS, coagulase-negative 
staphylococci; ECHO, echocardiography; HACEK, combination of Haemophilus species, Aggregatibacter species, Cardiobacterium hominis, Eikenella corrodens and Kingella kingae; IE, infective 
endocarditis; IV, intravenous; KUH, Karolinska University Hospital. 
  
APPENDIX IV. DISTRIBUTION OF BACTERIAL AETIOLOGIES, PREDISPOSING FACTORS 
AND OUTCOMES AMONG PATIENTS WITH IE AT THE KUH (PAPER IV) 
 
Prosthetic heart valve History of IV drug abuse >1 ECHO manifestation Surgical treatment for IE In-hospital mortality 
All patients, n (%) 92 (19) 156 (32) 83 (17) 139 (28) 33 (7) 
Staphylococcus aureus 28 (30), 0.39, 0.23-0.65; <0.01 122 (78), 6.72, 4.24-10.76; <0.01 36 (43), 0.78, 0.47-1.28; 0.30 61 (44), 0.77, 0.51-1.16; 0.19 21 (64), 1.93, 0.88-4.42; 0.07 
CoNS 8 (9), 2.29, 0.82-5.88; 0.06 2 (1), 0.19, 0.02-0.77; 0.01 11 (13), 4.65, 1.80-11.71; <0.01 10 (7), 1.88, 0.73-4.67; 0.13 2 (6), 1.28, 0.14-5.62; 0.67 
Viridans group streptococci 14 (15), 0.64, 0.32-1.20; 0.15 8 (5), 0.14, 0.06-0.30; <0.01 14 (17), 0.74, 0.37-1.41; 0.34 34 (24), 1.36, 0.82-2.22; 0.20 6 (18), 0.84, 0.28-2.16; 0.71 
Group B streptococci 1 (1), 0.43, 0.01-3.09; 0.70 0 (0) 2 (2), 1.10, 0.11-5.44; 1.00 3 (2), 0.95, 0.16-4.04; 1.00 1 (3), 1.38, 0.04-10.22;0.54 
Group D streptococci 3 (3), 3.34, 0.48-20.04; 0.13 0 (0) 1 (1), 0.82, 0.02-6.89; 1.00 4 (3), 3.46, 0.57-23.84; 0.10 0 (0) 
Group G streptococci 2 (2), 1.46, 0.14-8.33; 0.65 1 (1), 0.30, 0.01-2.40; 0.45 0 (0) 1 (1), 0.36, 0.01-2.83; 0.45 0 (0) 
Enterococcus faecalis 17 (18), 2.52, 1.25-4.93; <0.01 17 (11), 1.12, 0.57-2.16; 0.71 11 (13), 1.45, 0.64-3.05; 0.31 9 (6), 0.53, 0.22-1.14; 0.09 2 (6), 0.55, 0.06-2.29; 0.56 
HACEK 5 (5), 2.24, 0.58-7.39; 0.17 0 (0) 4 (5), 1.83, 0.41-6.38; 0.30 8 (6), 3.02, 0.93-9.96; 0.03 1 (3), 0.99, 0.03-6.94; 1.00 
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APPENDIX V. DISTRIBUTION OF ECHO MANIFESTATIONS, PREDISPOSING FACTORS AND 
OUTCOMES AMONG PATIENTS WITH IE AT THE KUH (PAPER IV) 
Values are presented as n, number of patients; (% of patients); odds ratio; 95% confidence interval; and P values. Statistically significant associations (P < 0.05) are shown in bold. CIED, cardiovascular 
implantable electronic device; IE, infective endocarditis; IV, intravenous; KUH - Karolinska University Hospital. 
 
 
 
History of IV drug abuse Surgical treatment for IE In-hospital mortality 
All patients, n (%) 156 (32) 139 (28) 33 (7) 
Aortic valve vegetation 31 (20), 0.28, 0.17-0.44; <0.01 72 (52), 2.14, 1.41-3.25; <0.01 17 (52), 1.76, 0.81-3.82; 0.12 
Mitral valve vegetation 44 (28), 0.48, 0.31-0.74; <0.01 64 (46), 1.45, 0.95-2.19; 0.07 15 (45), 1.29, 0.59-2.79; 0.48 
Tricuspid valve vegetation 86 (55), 17.54, 9.99-31.33; <0.01 19 (14), 0.47, 0.25-0.82; 0.01 3 (9), 0.34, 0.06-1.12; 0.08 
Pulmonary valve vegetation 7 (4), 7.85, 1.46-77.92; <0.01 1 (1), 0.31, 0.01-2.37; 0.46 0 (0) 
CIED-associated IE 1 (1), 0.09, 0.01-0.55; <0.01 18 (13), 8.60, 3.16-26.96; <0.01 2 (6), 1.28, 0.14-5.61; 0.67 
Perivalvular abscess 4 (3), 0.33, 0.08-0.97; 0.04 17 (12), 3.96, 1.72-9.34; <0.01 6 (18), 4.21, 1.29-11.81; <0.01 
Prosthetic heart valve 12 (8), 0.28, 0.13-0.53; <0.01 26 (19), 1.00, 0.58-1.69; 1.00 8 (24), 1.43, 0.54-3.41; 0.40 
